

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty disclosure information is located on the virtual platform under the continuing education module.

Planners and Managers

The PIM and Alzheimer's Association planners and managers have nothing to disclose.

Monday, July 27, 2020, AAIC Disclosures

12:00 a.m. — 11:59 p.m. Central Daylight Time (North America)

ODFRS1-01 A multiscale perspective on abnormal neuronal activity in early AD

ODFRS1-01-02 Introduction

Willem de Haan, M.D., Ph.D. *has nothing to disclose.*

Ronald E. van Kesteren, Ph.D. *has nothing to disclose.*

ODFRS1-01-03 Early dysregulation of neuronal activities in models of Alzheimer's Disease

Marc A Busche, Ph.D., M.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
Roche - Consulting Fees

ODFRS1-01-03 Network abnormalities and interneuron dysfunction in Alzheimer's disease

Jorge J Palop, Ph.D. *has nothing to disclose.*

ODFRS1-01-04 Hypersynchronization, a common feature along the AD process

Fernando Maestú, Ph.D. *has nothing to disclose.*

ODFRS1-01-05 Neuronal network hyperactivity in computational models of AD

Willem de Haan, M.D., Ph.D. *has nothing to disclose.*

ODFRS1-02 Alzheimer's Disease Apolipoprotein Pathology for Treatment Elucidation and Development: The ADAPTED project results

ODFRS1-02-01 Can OMICS data help us to understand the mechanism of APOE?

María Eugenia Sáez, Ph.D. *has nothing to disclose.*

THIS PRESENTATION IS NOT CME ACCREDITED

ODFRS1-02-02 Modelling AD – relevant pathophysiology in neurons, astrocytes and microglia from two complete sets of isogenic iPSC lines generated by the ADAPTED project

Alfredo Cabrera Socorro, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
Janssen Pharmaceutica - Salary

THIS PRESENTATION IS NOT CME ACCREDITED

ODFRS1-02-03 Characterization of transcriptional and proteomics changes in brain cells derived from isogenic hiPSCs reveals cell type and genotype specific mechanisms modified by APOE

Janina S. Ried, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

AbbVie Deutschland GmbH & Co KG - Salary

ODFRS1-02-04 Cross-omics studies of the role of apolipoprotein E in Alzheimer's disease and dementia: searching common pathways in patients, populations and cellular models

Cornelia M van Duijn, Ph.D. *has nothing to disclose.*

ODFRS1-03 Dysregulation of protein synthesis in neurodegeneration

ODFRS1-03-01 Regulation of ribosomal function by oligomeric tau

Lulu Jiang, M.D., Ph.D. *has nothing to disclose.*

ODFRS1-03-02 Ribosomal protein synthesis is decreased in tauopathy as revealed by non-canonical amino acid labelling

Harrison Tudor Evans *has nothing to disclose.*

ODFRS1-03-03 Presentation 3: Translational dysregulation promotes pathogenic events in tauopathies

Jose F. Abisambra, Ph.D. *has nothing to disclose.*

ODFRS1-03-04 Presentation 4: Exacerbation of tau pathology by pre-existing amyloidosis in novel transgenic mice

Jada Lewis, Ph.D. *has nothing to disclose.*

ODFRS1-04 Functionalizing Genetic Variants in Alzheimer's Disease

ODFRS1-04-01 Integration of Alzheimer's disease genetics and myeloid genomics reveals novel disease risk mechanisms

Edoardo Marcora, Ph.D. *has nothing to disclose.*

ODFRS1-04-02 Pathways to selective neuronal vulnerability

Karen E Duff, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Ceracuity LLC - Ownership Interest

ODFRS1-04-03 Integrating Human Brain Proteomes and Genome-Wide Association Results Implicates New Genes in Alzheimer's Disease

Alzheimer's Association International Conference® 2020

Thomas S Wingo, M.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
Parabon Nanolabs Inc - Contracted Research

ODFRS1-04-04 *In vivo* testing of the role of Alzheimer's disease coding variants

Michael Sasner, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
Denali Therapeutics - Contracted Research

ODFRS1-05 Genome-Metabolome-Phenome: Towards an Integrated Molecular Atlas for Alzheimer's Disease

ODFRS1-05-01 Genome-wide study of the human lipidome and links to Alzheimer' disease risk

Peter J Meikle, Ph.D. *has nothing to disclose.*

ODFRS1-05-02 A network-based, multi-omics Atlas for target identification and prioritization in Alzheimer's disease

Maria Wörheide *has nothing to disclose.*

ODFRS1-05-03 Integrative Metabolomics-Genomics Approach Reveals That Pathways Related to the Metabolism of Acylcarnitines and Amines are New Potential Targets of Alzheimer's Disease

Emrin Horgusluoglu-Moloch, Ph.D. *has nothing to disclose.*

ODFRS1-05-04 Serum metabolome informs neuroimaging biomarkers for Alzheimer's disease

Kwangsik Nho, Ph.D. *has nothing to disclose.*

ODFRS1-06 Imaging and biomarker correlates of genetic variants protective against AD

ODFRS1-06-01 Multimodal imaging correlates of the protective APOE2 allele

Colin Groot, MSc *has nothing to disclose.*

ODFRS1-06-03 Protective genetic variants in the *MS4A* gene cluster modulate microglial activity

Yuetiva Deming, Ph.D. *has nothing to disclose.*

ODFRS1-06-04 Genome-wide association studies for identifying novel genetic variants providing cognitive resilience against AD pathology

Timothy J. Hohman, Ph.D. *has nothing to disclose.*

ODFRS1-07 Impact of CNS insulin signaling in Alzheimer's disease

ODFRS1-07-01 Regulation of insulin transport across the blood-brain barrier by CNS insulin receptor signaling

Alzheimer's Association International Conference® 2020

Elizabeth Rhea, Ph.D. *has nothing to disclose.*

ODFRS1-07-02 Interactions between insulin, the blood-brain barrier, and beta-amyloid in Alzheimer's disease

Frederic Calon, Ph.D. *has nothing to disclose.*

ODFRS1-07-03 Loss of biliverdin reductase-A (BVR-A) impairs beneficial effects of CNS insulin on brain energy metabolism favoring the development of Alzheimer's disease (AD) neuropathology

Eugenio Barone, PharmD, Ph.D. *has nothing to disclose.*

ODFRS1-07-04 Developing CNS Therapeutics for Brain Insulin Resistance in Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI)

Konrad Talbot, Ph.D. *has nothing to disclose.*

ODFRS1-08 Lipids in AD and FTD; from genes to interventions.

ODFRS1-08-01 Genetics studies of Alzheimer's disease risk implicate clearance of lipid rich debris in myeloid cells

Alison M Goate, DPhil *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Athena Diagnostics - Royalty
Taconic Biosciences - Royalty

ODFRS1-08-02 25-hydroxycholesterol amplifies microglial IL-1beta production in an apoE isoform dependent manner

Wenjie Luo, Ph.D. *has nothing to disclose.*

THIS PRESENTATION IS NOT CME ACCREDITED

ODFRS1-08-03 A brain penetrant progranulin biotherapeutic rescues lysosomal and inflammatory phenotypes in the brain of *Grn* knockout mice

Todd Logan, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Denali Therapeutics Inc. - Salary, Ownership Interest

ODFRS1-08-04 Efavirenz as a cholesterol-targeting drug for AD

Irina A Pikuleva, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Merck - Consulting Fees

ODFRS1-09 The locus coeruleus: nexus of behavioral and cognitive problems in dementia

ODFRS1-09-01 Alzheimer pathology in the human ascending reticular activating system: early and severe

Lea Tenenholz Grinberg, M.D., Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

CuraSen - Consulting Fees

ODFRS1-09-02 Noradrenergic responsiveness supports selective attention across the adult lifespan

Martin J Dahl, Ph.D. *has nothing to disclose.*

ODFRS1-09-03 The locus coeruleus on stress: Bridging the translational gap

Johannes Bohacek, Ph.D. *has nothing to disclose.*

ODFRS1-09-04 Hypoconnectivity between Locus Coeruleus and Medial Temporal Lobe during Novelty predicts Accelerated A β -related Cognitive Decline

Nina Engels, MSc *has nothing to disclose.*

ODO1-01 Basic Science and Pathogenesis: Genetics And Omics Of AD

ODO1-01-01 Network analysis to identify proteomic markers for brain aging and dementia in healthy older adults

Meghan I Short, Ph.D. *has nothing to disclose.*

ODO1-01-02 *RPS16* and *NOL6* splice region variants are associated with early onset Alzheimer's Disease

Yann Le Guen, Ph.D. *has nothing to disclose.*

ODO1-01-03 *ABCA7* PTC mutation carriers present with Alzheimer's disease pathology and cerebral amyloid angiopathy.

Elisabeth Hens, M.D. *has nothing to disclose.*

ODO1-01-04 The late-onset Alzheimer's disease genetic risk factor CD2AP impacts synapses via actin dynamics

Farzaneh S. Mirfakhar, Msc. *has nothing to disclose.*

ODO1-01-05 Cell-type Specific eQTLs (ct-eQTLs) Associated with Alzheimer Disease in Blood and Brain Tissue

Devanshi Patel, MS *has nothing to disclose.*

ODO1-01-06 Synonymous variant *rs2405442* in *PILRA* is associated with Alzheimer's disease and affects RNA expression by destroying a ramp sequence

Justin Miller, Ph.D. *has nothing to disclose.*

ODO1-02 Basic Science and Pathogenesis: Inflammation: From Basic Science To Biomarkers

ODO1-02-01 Mechanisms of neuroinflammation with ApoE4 implicate cPLA2

Victoria A Solomon, BS *has nothing to disclose.*

ODO1-02-02 Leveraging mouse genetic diversity to investigate the role of brain myeloid cells in Alzheimer's disease

Hongtian Stanley Yang, Ph.D. *has nothing to disclose.*

PENDING CME CREDIT APPROVAL

ODO1-02-03 Impact of modulating gut bacteria using antibiotic, probiotic, and prebiotic interventions using the *App^{NL-G-F}* mouse model of Alzheimer disease

Harpreet Kaur, Ph.D. *has nothing to disclose.*

ODO1-02-04 Association between microbiota dysbiosis and endothelial dysfunction in Alzheimer's Disease: an in-vivo cross-sectional study

Annamaria Cattaneo, Ph.D. *has nothing to disclose.*

ODO1-02-05 APOEε4, MICROBIOTA AND INFLAMMATION IN HEALTHY ELDERLY

Maira Marizzoni, Ph.D. *has nothing to disclose.*

ODO1-02-06 Single-cell profiling of circulating and brain-resident immune cells in a mouse model for amyloidosis and in aged mice

Lynn van Olst, MSc *has nothing to disclose.*

ODO1-03 Development of New Models and Analysis Methods: Multi-system Platform Models Of ADRD

ODO1-03-01 Generation of non-human primate models of Alzheimer's disease

Hiroki Sasaguri, M.D., Ph.D. *has nothing to disclose.*

ODO1-03-02 The Viral Protein Corona Directs Viral Pathogenesis and Amyloid Aggregation

Kariem Ezzat, Ph.D. *has nothing to disclose.*

ODO1-03-03 Assessment of a novel tau propagation pathway from layer II medial entorhinal cortical neurons to CA1 pyramidal neurons as an early Braak stage mouse model

Jean Christophe Delpech, Ph.D. *has nothing to disclose.*

ODO1-03-04 Alzheimer-like pathology in trisomy 21 cerebral organoids amenable to pharmacological inhibition reveals BACE2 as a gene-dose-sensitive AD-suppressor in human brain

Dean Nizetic, M.D. Ph.D. *has nothing to disclose.*

THIS PRESENTATION IS NOT CME ACCREDITED

ODO1-03-05 WHICH TAU TARGET TO SELECT FOR DRUG DISCOVERY? INSIGHTS FROM AN ADVANCED QUANTITATIVE SYSTEMS PHARMACOLOGY MODEL

Hugo Geerts, Ph.D., bachMed, PharmaMBA *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

In Silico Biosciences - Ownership Interest

ODO1-04 Development Of New Models And Analysis Methods: Novel Imaging Analysis

ODO1-04-01 Application of Machine Learning to Predict Amyloid, Metabolic, and Structural Neuroimaging Biomarkers in the Progression of Autosomal Dominant Alzheimer Disease

Patrick H Lockett, Ph.D. *has nothing to disclose.*

ODO1-04-02 Brain network dysfunction associated with blood neurofilament light chain in autosomal dominant Alzheimer disease

Muriah D Wheelock, Ph.D. *has nothing to disclose.*

ODO1-04-03 Network Diffusion Model enhances predictions of future tau-PET burden in Alzheimer's patients

Pablo F. Damasceno, Ph.D. *has nothing to disclose.*

ODO1-04-04 fMRI complexity is associated with tau-PET and cognitive decline in Alzheimer's disease

Kay Jann, Ph.D. *has nothing to disclose.*

ODO1-04-05 Behavior and Amyloid Profiles Modify the Association of Tauopathy/Neurodegeneration and Cognitive Decline in Alzheimer's Disease

Xinting Ge, Ph.D. *has nothing to disclose.*

ODO1-04-06 Amyloid angiopathy may contribute to white-matter hyperintensities in Alzheimer's disease

Parnesh Raniga, Ph.D. *has nothing to disclose.*

ODO1-05 Genetics: Genetics And Omics Of AD I

ODO1-05-01 Single-nuclei chromatin accessibility and transcriptomics unravels altered human oligodendrocyte heterogeneity in Alzheimer's disease

Vivek Swarup, Ph.D. *has nothing to disclose.*

ODO1-05-02 Single-nuclei RNA-seq of brains carriers of high-risk variants and Mendelian mutations

Jorge L. Del-Aguila, Ph.D. *has nothing to disclose.*

ODO1-05-03 Transcript analysis using long-read sequencing reveals the complex splicing profile of AD-associated gene *ABCA7*

Lena Duchateau, MSc *has nothing to disclose.*

ODO1-05-04 Single nuclei RNA-seq data analysis identifies glial cell lineages associated with Alzheimer's disease severity

Benjamin A Logsdon, Ph.D. *has nothing to disclose.*

ODO1-05-05 Cell-type-specific and sex-dependent changes in the chromatin accessibility landscape in late-onset Alzheimer's disease brains

Ornit Chiba-Falek, Ph.D. *has nothing to disclose.*

ODO1-05-06 Brain Transcriptome Wide Association Study (TWAS) Implicates 8 Genes Across 6 Loci in Alzheimer's Disease.

Jake Gockley, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
Celgene - Salary

ODO1-06 Genetics: Genetics And Omics Of AD II

ODO1-06-01 Tissue-Specific Genetically Regulated Expression in Late-Onset Alzheimer's Disease Implicates Risk Genes within Known and 30 Novel Loci

Hung-Hsin Chen, MS *has nothing to disclose.*

ODO1-06-02 Mechanism for the protective effect of *APOE* ϵ 2 against Alzheimer disease is linked to tau and the classical complement pathway

Gyungah R Jun, Ph.D. *has nothing to disclose.*

ODO1-06-03 The Role of Native American Ancestry in Alzheimer's Disease and Related Dementias.

Giuseppe Tosto, M.D., Ph.D. *has nothing to disclose.*

ODO1-06-04 Alzheimer's genetic risk factor *FERMT2* (Kindlin-2) controls axonal growth and synaptic plasticity in an APP-dependent manner

Julien Chapuis, Ph.D. *has nothing to disclose.*

ODO1-06-05 Genome-Wide Meta-Analysis of Late-Onset Alzheimer's Disease Using Rare Variant Imputation in 65,602 Subjects Identifies Risk Loci with Roles in Memory, Neurodevelopment, and Cardiometabolic Traits: The International Genomics of Alzheimer's Project (IGAP)

Adam C Naj, Ph.D. *has nothing to disclose.*

ODO1-06-06 Brain transcriptomes and plasma proteins reveal up-regulation of a pro-inflammatory signature in *APOE* ϵ 4 carriers

Sudeshna Das, Ph.D. *has nothing to disclose.*

ODO1-07 Genetics: Genetics Of Cognitive Aging, Other Dementia, And Endophenotypes

ODO1-07-01 *APOE* stratified genome-wide gene-based analysis of episodic memory trajectories in a multi-ethnic sample of 24,769 elderly

Sandra Barral, Ph.D. *has nothing to disclose.*

ODO1-07-02 Proteogenomic analysis of cerebrospinal fluid reveals causal role of proteins from the autophagy-lysosome pathway in Parkinson's disease

Bruno A. Benitez, M.D. *has nothing to disclose.*

ODO1-07-03 Whole Genome Sequence Association Analyses of Brain Volumes in the TOPMed Program

Chloé Sarnowski, Ph.D. *has nothing to disclose.*

ODO1-07-04 Alzheimer's Polygenic Risk Score in general population reveals new biomarkers for early diagnosis

Slim Karkar, Ph.D. *has nothing to disclose.*

ODO1-07-05 Genome-wide Analysis of Longitudinal Alzheimer's Disease Biomarker Endophenotypes

Tanner Y. Jacobson *has nothing to disclose.*

ODO1-07-06 Genome-wide DNA methylation signatures of tau and amyloid neuropathology

Isabel Castanho, Ph.D. *has nothing to disclose.*

ODO1-08 Genetics: Molecular Genetics of AD And ADRD

ODO1-08-01 Increased *APOEε4* expression is associated with reactive A1 astrocytes and may confer the difference in Alzheimer Disease risk from different ancestral backgrounds

Katrina Celis, M.D. *has nothing to disclose.*

ODO1-08-02 Functional Interpretation of Genetic Risk Loci for Dementia using a Protein Quantitative Trait Loci (pQTLs) Approach in Cerebrospinal Fluid

Lianne M. Reus *has nothing to disclose.*

ODO1-08-03 iPSC-Derived Neurons and Microglia with an African-Specific *ABCA7* Frameshift Deletion Have Impaired Function

Holly N. Cukier, Ph.D. *has nothing to disclose.*

ODO1-08-04 Functional characterization of an Alzheimer disease-associated deletion in *SORL1*

Derek M. Dykxhoorn, Ph.D. *has nothing to disclose.*

ODO1-08-05 Immune response and endocytosis pathways are associated with the *resilience* against Alzheimer's Disease

Niccoló Tesi, MSc *has nothing to disclose.*

ODO1-08-06 Transcriptome characterization of the motor cortex suggests microglial-related key events due to TDP-43 aberrant inclusions

Oriol Dols-Icardo, Ph.D. *has nothing to disclose.*

ODO1-09 Human Neuropathology: AD Neuropathology

ODO1-09-01 Brain iron burden is associated with accelerated cognitive decline in Alzheimer's disease

Ashley I Bush, M.D., Ph.D. *has nothing to disclose.*

ODO1-09-02 The amyloid plaque proteome in different subtypes of Alzheimer's disease

Eleanor Drummond, Ph.D. *has nothing to disclose.*

ODO1-09-03 Differential protein expression identified by digital spatial profiling (DSP) in the hippocampi of resilient individuals.

Jamie M Walker, M.D. Ph.D. *has nothing to disclose.*

ODO1-09-04 TRPML1: A novel therapeutic target to remediate endolysosomal pathology in Alzheimer's disease

Cora O'Neill, Ph.D. *has nothing to disclose.*

ODO1-09-05 An integrated epigenetic-genetic study of neuropathology in the Brains for Dementia Research Cohort.

Eilis Hannon, Ph.D. *has nothing to disclose.*

ODO1-09-06 EPIGENOMIC FEATURES RELATED TO MICROGLIA ARE ASSOCIATED WITH ATTENUATED EFFECT OF APOE ε4 ON ALZHEIMER'S DISEASE RISK IN HUMANS

Yiyi Ma, M.D., Ph.D. *has nothing to disclose.*

ODO1-10 Human Neuropathology: Non-AD Neurodegenerative Disease Neuropathology

ODO1-10-01 Pattern of degeneration of sleep-wake nuclei correlates with objective sleep measurements in progressive supranuclear palsy: a quantitative clinicopathological study

Jun Yeop Oh *has nothing to disclose.*

ODO1-10-02 The etiology of long-term stable mild cognitive impairment

Manu J. Sharma, BSc *has nothing to disclose.*

ODO1-10-03 A prospective long-term study of TDP-43 pathology in Alzheimer's disease aggression

Audun Osland Vik-Mo, M.D. PHD *has nothing to disclose.*

ODO1-10-04 OLIGODENDROGLIAL ALTERATIONS IN FTD CAUSED BY C9ORF72 EXPANSION

Sonia Sirisi Dolcet, Ph.D. *has nothing to disclose.*

ODO1-10-05 Cellular vulnerability in Lewy body diseases

Daniel Erskine, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
Sosei Heptares - Contracted Research

ODO1-10-06 Associations of Automatically Segmented Enlarged Perivascular Spaces with Neuropathology and Cognitive Decline in a Community Cohort of Older Adults

Carles Javierre Petit, MS *has nothing to disclose.*

ODO1-11 Molecular & Cell Biology: Endo-Lysosomal/Trafficking Dysfunction

ODO1-11-01 A novel interaction between AD risk genes synaptojanin 1 and reticulon-3 potentially impacts synaptic function and endo-lysosomal trafficking during disease development and progression

Dongming Cai, M.D., Ph.D. *has nothing to disclose.*

ODO1-11-02 Depletion of the AD risk gene *SORL1* selectively impairs neuronal endosomal traffic independent of amyloidogenic APP processing.

Jessica E. Young, Ph.D. *has nothing to disclose.*

ODO1-11-03 Neuron-selective induction of granulovacuolar degeneration bodies: A lysosomal stress response to tau aggregation?

Wiep Scheper, Ph.D. *has nothing to disclose.*

ODO1-11-04 Late-onset Alzheimer's Disease-associated gene, CPAM.D.8, increases b-CTF and affects APP processing through regulation of the autophagy-lysosome pathway

Wei Qin, M.D., Ph.D. *has nothing to disclose.*

ODO1-11-05 A Transcriptional Mechanism for Retromer Misregulation

Cláudio Gouveia Roque, Ph.D. *has nothing to disclose.*

ODO1-12 Molecular & Cell Biology: Importance Of Abeta/Amyloid In Brain Changes

ODO1-12-01 Distribution of Isomerized and Racemized Amyloid β Isoforms in the Sporadic Alzheimer's Disease using Ion-Mobility Mass Spectrometry

Soumya Mukherjee, Ph.D. *has nothing to disclose.*

THIS PRESENTATION IS NOT CME ACCREDITED

ODO1-12-02 Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor Exerts Greater Efficacy than Atorvastatin on Ameliorating Cognitive Impairment in High-fat Diet Induced Obesity

Busarin Arunsak, B.Sc. *has nothing to disclose.*

CME CREDIT APPROVAL PENDING

ODO1-12-03 Stimulation of ADAM10 and decrease in plaques by a sleep-inducing supplement

Kalipada Pahan, Ph.D. *has nothing to disclose.*

ODO1-12-04 Understanding Trisomy 21 associated alterations in APP/amyloid- β biology using mouse models

Frances K Wiseman, Ph.D. *has nothing to disclose.*

ODO1-12-05 Abnormally cross-talking between gut and brain in Alzheimer's disease models

Qiong Wang, M.D., Ph.D. *has nothing to disclose.*

ODO1-12-06 Elucidating the relationship between TGF- β signaling and Alzheimer's disease

Cara L Croft, Ph.D. *has nothing to disclose.*

ODO1-13 Molecular & Cell Biology: Inflammatory And Microglia-Mediated Mechanisms In AD

ODO1-13-01 NLRP3 inflammasome activation regulates microglial migration

Roisin M. McManus, Ph.D. *has nothing to disclose.*

ODO1-13-02 Single nuclear RNA sequencing reveals microglia diversity associated with cognitive resilience in the AD-BXD mouse model of human Alzheimer's disease

Sarah E Heuer, BS *has nothing to disclose.*

ODO1-13-03 Single cell RNA sequencing of human microglia uncovers a subset that is associated with Alzheimer's disease

Marta Olah, Ph.D. *has nothing to disclose.*

ODO1-13-04 Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer's disease

David Gate, Ph.D. *has nothing to disclose.*

ODO1-13-05 A NOVEL FUNCTION OF BACE1 IN IMMUNE SYSTEM

Linbin Dai, Ph.D. *has nothing to disclose.*

ODO1-14 Molecular & Cell Biology: Neurodegeneration Versus Neuroprotection

ODO1-14-01 Protective low expression of PU.1 reduces microglial inflammatory and phagocytic response

Anna A Pimenova, Ph.D. *has nothing to disclose.*

ODO1-14-02 Alzheimer-associated circular RNA *circHOMER1* regulates synaptic gene expression and cognition

Nikolaos Mellios, M.D., Ph.D. *has nothing to disclose.*

ODO1-14-03 Tau Hyperphosphorylation in the Retinal Ganglion Cells is Attenuated upon Silencing of Shp2 Phosphatase

Vivek K Gupta, Ph.D. *has nothing to disclose.*

ODO1-14-04 Neurotensin Agonist Alleviates Metabolic Disturbance, Neuropathology, and Cognitive Decline in High-Fat Diet-Induced Obese Rats

Napatsorn Saiyasit, BSc *has nothing to disclose.*

CME CREDIT APPROVAL PENDING

ODO1-14-05 Effects of an SGLT2 Inhibitor on Cognition in Diabetes Involving Amelioration of Deep Cortical Cerebral Blood Flow Autoregulation and Pericyte Function

Shaoxun Wang *has nothing to disclose.*

ODO1-14-06 TgF344-AD rats exhibit cognitive reserve despite continual A β and tau accumulation

Christopher D Morrone, Ph.D. *has nothing to disclose.*

ODO1-15 Molecular & Cell Biology: Tau-Related Mechanisms

ODO1-15-01 Extracellular vesicles derived from post-mortem human brain tissue contain seed-competent C-terminal tau fragments, and provide proteomic clues to the identity of selectively vulnerable cell populations in human tauopathies

Stephanie L Fowler, Ph.D. *has nothing to disclose.*

ODO1-15-02 Amyloid- β Oligomer-induced, Tau-dependent Dysregulation of Mitochondrial DNA Replication is mediated by SOD1

Andrés Norambuena, Ph.D. *has nothing to disclose.*

ODO1-15-03 β -arrestin2 oligomers impair the clearance of pathological tau and increase tau aggregates

JungA Alexa Woo, Ph.D. *has nothing to disclose.*

ODO1-15-04 Leveraging Amino Acid Sensors as Therapeutic Targets for Tauopathies and Related Dementias

Daniel C Lee, Ph.D. *has nothing to disclose.*

Alzheimer's Association International Conference® 2020

ODO1-15-05 Chronic intermittent hypoxia enhances tau seeding and propagation and exacerbates Alzheimer's-like memory and synaptic plasticity deficits and molecular signatures

Ana C. Pereira, M.D. *has nothing to disclose.*

ODO1-15-06 Synaptic stimulation protects against pathological tau by enhancing lysosomal degradation

Davide Tampellini, Ph.D. *has nothing to disclose.*

ODO1-16 [Alzheimer's Imaging Consortium]: Neuroimaging of Atypical AD: A First Joint PIA Session

ODO1-16-01 Distribution of pathological hallmarks and association with post-mortem MRI cortical thickness in typical and atypical Alzheimer's disease

Laura E. Jonkman, Ph.D. *has nothing to disclose.*

ODO1-16-02 Differential association between tau pathology and longitudinal cortical atrophy in subtypes of Alzheimer's Disease

Rosaleena Mohanty, Ph.D. *has nothing to disclose.*

ODO1-16-03 Tau pathology in posterior DMN is related to aberrant SN-DMN network connectivity in atypical Alzheimer's disease

Deepti Putcha, Ph.D. *has nothing to disclose.*

ODO1-16-04 Intrinsic connectivity of the human brain provides scaffold for tau aggregation in clinical variants of Alzheimer's disease

Joseph Therriault, BSc *has nothing to disclose.*

ODO1-16-05 Tau and amyloid association with functional connectivity in atypical Alzheimer's disease

Irene Sintini, Ph.D. *has nothing to disclose.*

ODO1-16-06 Associations between cortical microstructural breakdown and tau and amyloid deposition in typical and atypical Alzheimer's disease

Philip SJ Weston, Ph.D. *has nothing to disclose.*

SEC1-01 Emerging Concepts in Basic Science: Neuroimmune Single Cell RNA Sequencing

SEC1-01-01 Astrocyte diversity in the context of neuroimmune pathology

Francisco J. Quintana, Ph.D. *has nothing to disclose.*

Alzheimer's Association International Conference® 2020

SEC1-01-02 Novel mechanisms of AD pathogenesis identified by scRNA-seq of AD patients and experimental models

Marco Colonna, M.D. *has nothing to disclose.*

SEC1-01-03 Dissecting the Alzheimer's brain: from single cells to cellular communities

Naomi Habib *has nothing to disclose.*

SFRS1-01 EV or not EV? Extracellular propagation of AD pathogenic molecules and evaluation of brain cell-derived extracellular vesicles from patient plasma as EV biomarkers

SFRS1-01-01 Tau immunotherapy rescues cognitive impairment by clearing extracellular tau

Khalid Iqbal, Ph.D. *has nothing to disclose.*

SFRS1-01-02 Elucidating the pathogenic mechanisms of AD brain-derived tau-containing extracellular vesicles: Highly transmissible and preferential propagation to GABAergic neurons

Tsuneya Ikezu, M.D., Ph.D. *has nothing to disclose.*

SFRS1-01-03 Plasma Extracellular Vesicles of neuronal and astrocytic origins: biomarker carriers and pathogenic effectors in Alzheimer's Disease

Dimitrios Kapogiannis, M.D. *has nothing to disclose.*

SFRS1-01-04 Pathological significance of neuron-derived EVs in Alzheimer's disease and its potential as biomarkers

Takashi Kudo, M.D., Ph.D. *has nothing to disclose.*

SO1-01 Developing Topic Session: The Key Players in Alzheimer's Disease

SO1-01-01 Hierarchical involvement of molecular players in human neocortex in the course of preclinical and symptomatic Alzheimer's disease

Xiaohang Li, Ph.D. *has nothing to disclose.*

SO1-01-02 A family-based genetic study identifies mutations in *TLR9* impairing receptor activation: a role for innate immunity in AD pathogenesis

Rita Cacace, Ph.D. *has nothing to disclose.*

SO1-01-03 Oligomeric Amyloid-Beta 1–42 Inhibits Antigen Presentation

Maria Teresa Ferretti, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
Eli Lilly - Consulting Fees

SO1-01-04 Loss of Synaptogyrin-3 rescues Tau-induced memory defects and synaptic loss in the presence of microglial activation

Pablo Largo-Barrientos *has nothing to disclose.*

SO1-01-05 CHIMERA Traumatic Brain Injury Induces Tauopathy in the rTg4510 Mice

Wai Hang Cheng, Ph.D. *has nothing to disclose.*

THIS PRESENTATION IS NOT CME ACCREDITED

SO1-01-06 From Genes to Cognition: *Octodon degus*, an animal model for AD translational research

Patricia Cogram, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Healx/Fragile X Syndrome - Contracted Research
Sunovion/Fragile X Syndrome - Contracted Research
Neuren/Fragile X Syndrome - Contracted Research

SEC1-02 Emerging Concepts in Basic Science: Therapeutic Benefit of Adapting Proteostasis in Neurodegeneration

SEC1-02-01 From chemical chaperones to proteostatic approach to ameliorate neurodegenerative diseases

Jeff Kelly *has nothing to disclose.*

SEC1-02-02 Benefit of protein homeostasis manipulations with arimocloamol

Linda Greensmith *has nothing to disclose.*

SEC1-02-03 Power and benefit of eIF2a phosphatase inhibition in neurodegenerative diseases

Anne Bertolotti *has nothing to disclose.*

SEC1-02-04 Unmasking genetic modifiers of neurodegeneration

Susan Ackerman *has nothing to disclose.*

SFRS1-02 Microbiome in Alzheimer's Disease: Pathogenesis and Treatment Implications

SFRS1-02-01 Overview of Immune System in AD

Michael T. Heneka, M.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Alector - Consulting Fees
IFM Therapeutics - Consulting Fees

THIS PRESENTATION IS NOT CME ACCREDITED

SFRS1-02-02 Causal Communication Between Gut Microbiota Dysbiosis and Neuroinflammation in Alzheimer's Disease and Therapeutic Intervention by Oligomannate

Meiyu Geng, Ph.D. *has nothing to disclose.*

SFRS1-02-03 Modulation of Amyloid Deposition and Neuroinflammation by the Microbiome

Sangram S. Sisodia, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Green Valley Therapeutics, Inc - Consulting Fees

AZ Therapies, Inc - Consulting Fees

SFRS1-02-04 Identification and Characterization of Immune-Focused Therapeutic Targets in the MODEL-AD and TREAT-AD Consortia

Bruce T. Lamb, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

AVROBIO - Consulting Fees

SSYM1-01 Mechanisms Of White Matter Damage

SSYM1-01-01 Understanding the Pathophysiology of Amyloid-Related Imaging Abnormalities (ARIA) following A β immunotherapy

James AR Nicoll, M.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Biogen - Consulting Fees

SSYM1-01-02 Biomarkers Of Vascular Cognitive Impairment And Dementia; Informing Disease Mechanisms

Donna M Wilcock, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Alector - Consulting Fees

Avrobio - Consulting Fees

SSYM1-01-03 Trauma-Related Axonal Damage

Victoria Johnson *has nothing to disclose.*

SSYM1-01-04 Neuroimaging of White Matter Hyperintensities (WMH)

Joanna M Wardlaw, CBE, MBChB, M.D., FRCR, FRCP, FMedSci *has nothing to disclose.*

SEC1-03 Emerging Concepts in Basic Science: Molecular Mechanisms of Neuropathological and Clinical Heterogeneity in Alzheimer's Disease

SEC1-03-01 The Role of Innate Immunity in Alzheimer's Disease

Rudolph E Tanzi, Ph.D. *has nothing to disclose.*

SEC1-03-02 Synaptic Pathology in Alzheimer's Disease

Thomas J. Montine, M.D., Ph.D. *has nothing to disclose.*

SEC1-03-03 Human Brain Resilience to Alzheimer's Pathology

Teresa Gomez-Isla, M.D., Ph.D. *has nothing to disclose.*

SEC1-03-04 Tau molecular diversity contributes to clinical heterogeneity in Alzheimer's disease

Simon Dujardin, Ph.D. *has nothing to disclose.*

SFRS1-03 Towards a better knowledge of the genetics of Alzheimer's disease, The European Alzheimer Disease biobank (EADB) consortium

SFRS1-03-01 TopMed-imputed genome-wide association study of Alzheimer's disease in more than 100,000 European samples from the EADB project

Céline Bellenguez, Ph.D. *has nothing to disclose.*

SFRS1-03-02 A longitudinal GWAS in patients with mild cognitive impairment identifies modifiers for the speed of cognitive decline

Luca Kleinedam, MSc *has nothing to disclose.*

SFRS1-03-03 Novel genetic effects on Amyloid and Tau protein levels in cerebrospinal fluid

Iris E Jansen, Ph.D. *has nothing to disclose.*

SFRS1-03-04 Transcriptome-based Analyses of EADB Reveal New Insights Into Alzheimer's Disease

Fahri Küçükali, MSc *has nothing to disclose.*

SSYM1-02 Immunity In The Aging Or Diseased Brain

SSYM1-02-01 The Bidirectional Communication Between The Brain And The Systemic Immune System In Aging

Marina Lynch, Ph.D. *has nothing to disclose.*

SSYM1-02-02 Trem2- independent activity of PD-L1 immunotherapy in modifying Alzheimer's disease in mouse models

Michal Schwartz, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
IBC - Consulting Fees

SSYM1-02-03 Microglial Immune Memory and Metabolic Reprogramming Modifies Amyloid Structure And Neuronal Dystrophy In Mouse Models Of Alzheimer's Pathology

Jonas J. Neher, Dr. *has nothing to disclose.*

SEC1-04 Emerging Concepts in Basic Science: Panel Discussion

SEC1-04-01 Panel Discussion

Anne Bertolotti *has nothing to disclose.*

Teresa Gomez-Isla, M.D., Ph.D. *has nothing to disclose.*

Francisco J. Quintana, Ph.D. *has nothing to disclose.*

SFRS1-04 Targeting Cerebrovascular Pathology in Alzheimer's disease: the Pro's and Con's of Intensive Blood Pressure Lowering Treatment in AD.

SFRS1-04-01 Is dysregulation of cerebral perfusion an early marker and cause of MCI & AD?

Vasilis Marmarelis, Ph.D. *has nothing to disclose.*

SFRS1-04-02 Carotid Stiffness is Associated with Brain Amyloid- β Burden in Amnesic Mild Cognitive Impairment

Rong Zhang, Ph.D. *has nothing to disclose.*

SFRS1-04-03 Cerebral Hemodynamics using BOLD MRI in MCI

Brandon Henley, Ph.D. *has nothing to disclose.*

SFRS1-04-04 Cerebral autoregulation in patients with MCI and dementia due to Alzheimer's disease: effects of blood pressure lowering on CBF.

Jurgen A.H.R. Claassen, M.D., Ph.D. *has nothing to disclose.*

Tuesday, July 28, 2020, AAIC Disclosures

12:00 a.m. — 11:59 p.m. Central Daylight Time (North America)

ODFRS2-01 Developments in clinical, radiological and biomarker measurements for the detection and monitoring of early-stage frontotemporal dementia and implications for treatment development

ODFRS2-01-01 Psychiatric symptoms in the early detection and differential diagnosis of FTD

Simon Ducharme, M.D., MSc *has nothing to disclose.*

ODFRS2-01-02 Preclinical features of familial FTD

Lize C. Jiskoot, Ph.D. *has nothing to disclose.*

ODFRS2-01-03 CSF biomarkers for Frontotemporal Dementia and its pathological subtypes

Marta Del Campo, Ph.D. *has nothing to disclose.*

ODFRS2-01-04 Latent disease models estimate symptom onset in familial frontotemporal lobar degeneration and enable novel designs for early-stage clinical trials

Adam M. Staffaroni, Ph.D. *has nothing to disclose.*

ODFRS2-02 Doctor AI: Making computers explain their decisions

ODFRS2-02-01 Visual attention as a model for interpretable neuroimage classification in dementia

James Cole, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
Brain Key - Ownership Interest

ODFRS2-02-02 Visualization of deep learning relevance maps for AD detection

Kerstin Ritter, Ph.D. *has nothing to disclose.*

ODFRS2-02-03 Data-driven approach reveals heterogeneity and region-specific association of white matter hyperintensities with the APOE genotype

Mohamad Habes, Ph.D. *has nothing to disclose.*

ODFRS2-02-04 Deep learning models for generating diagnostic explanations

Martin Dyrba, Ph.D. *has nothing to disclose.*

ODFRS2-03 Early imaging changes in cognitively normal subjects at risk of late onset AD

ODFRS2-03-01 Mesoscopic compensations for microscopic impairments in mid-age individuals with family history of dementia

Li Su, Ph.D. *has nothing to disclose.*

ODFRS2-03-02 Multifaceted pattern of longitudinal imaging changes in cognitively normal midlife adults: The PREVENT-Dementia study

Elijah Mak, Ph.D. *has nothing to disclose.*

ODFRS2-03-03 Polygenic-wide analysis to assess the impact of genetic risk profiles on brain morphometry in the ALFA study.

Natalia Vilor-Tejedor, Ph.D. *has nothing to disclose.*

ODFRS2-03-04 Impact of the ApoE gene on amyloid deposition in participants with abnormal soluble amyloid levels

Raffaele Cacciaglia, Ph.D. *has nothing to disclose.*

ODFRS2-04 EEG biomarkers of Alzheimer's disease in pre-symptomatic and symptomatic patients: multimodal validation from international projects

ODFRS2-04-01 Multimodal phenotyping of synaptic damage along Alzheimer disease continuum

Vesna Jelic, M.D. Ph.D. *has nothing to disclose.*

ODFRS2-04-02 Using spatial filters to study regional reorganization of brain connectivity in familial early onset AD (PSEN1 E280A)

Francisco García *has nothing to disclose.*

ODFRS2-04-03 A study of alpha desynchronization, heart rate, and MRI during Stroop testing unmasks pre-symptomatic Alzheimer's disease

Xianghong Arakaki, M.D., Ph.D. *has nothing to disclose.*

ODFRS2-04-04 Multimodal screening for neurodegeneration in preclinical Alzheimer's disease using EEG, ApoE4 genotype, neuropsychological and MRI data

Stéphane Epelbaum, M.D., Ph.D. *has nothing to disclose.*

ODFRS2-05 Molecular imaging of novel biomarkers for neurodegeneration and ADRD

CME CREDIT APPROVAL PENDING

ODFRS2-05-01 [11C]MPC-6827, a microtubule-based PET imaging tracer: a potential early imaging biomarker for AD and other ADRDs

Kiran Solingapuram Sai, Ph.D. *has nothing to disclose.*

ODFRS2-05-02 Synaptic vesicle protein SV2A imaging with [11C]UCB-J as a novel biomarker of neurodegeneration in Alzheimer's disease

Barbara B. Bendlin, Ph.D. *has nothing to disclose.*

ODFRS2-05-03 In vivo measurement of widespread synaptic loss and associated tau accumulation in early Alzheimer's disease

Adam P. Mecca, M.D., Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eisai, Inc. - Contracted Research

Genetech, Inc. - Contracted Research

ODFRS2-05-04 PBR28 brain PET imaging with lipopolysaccharide challenge for the study of microglia function in Alzheimer's disease

Arash Salardini, M.D. *has nothing to disclose.*

ODFRS2-06 Multi-omics and big data analytics: from understanding disease heterogeneity to precision diagnostics

ODFRS2-06-01 Imaging Genomics in the ENIGMA consortium

Paul M Thompson, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Biogen, Inc. - Contracted Research

ODFRS2-06-02 From systems biology to precision medicine: Leveraging heterogeneity

Andrew J. Saykin, PsyD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eli Lilly - Contracted Research

Avid Radiopharmaceuticals -

Springer-Nature Publishing -

ODFRS2-06-03 Characterising the spatiotemporal heterogeneity of neurodegenerative diseases using Subtype and Stage Inference

Alexandra L. Young, Ph.D. *has nothing to disclose.*

ODFRS2-06-04 Data-driven biomarker approaches to disentangle mixed pathologies in AD

Duygu Tosun, Ph.D. *has nothing to disclose.*

ODFRS2-07 Person-centered prediction of tau spreading in Alzheimer's disease and related disorders

ODFRS2-07-01 Patient-Tailored, Connectivity-Based Forecasts of Spreading Brain Atrophy in Frontotemporal Dementia

Jesse Brown, Ph.D. *has nothing to disclose.*

ODFRS2-07-02 Accounting for systematic spatiotemporal variation improves connectome-based models of tau spreading in human Alzheimer's disease

Jacob W Vogel, BA *has nothing to disclose.*

ODFRS2-07-03 Disrupted brain dynamics across the Alzheimer's disease spectrum is related to tau accumulation

Hugo Botha, M.B., Ch.B. *has nothing to disclose.*

ODFRS2-07-04 Modeling patient-specific tau spreading patterns in Alzheimer's disease – towards precision medicine

Nicolai Franzmeier, Ph.D. *has nothing to disclose.*

ODFRS2-08 Refining clinical trials for dementia prevention

ODFRS2-08-01 Using a novel clinical prediction algorithm to enhance clinical trials in Alzheimer's disease

Yaakov Stern, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
Columbia University - Receipt of Intellectual Property Rights/Patent Holder
Essai - Consulting Fees

ODFRS2-08-02 Fluid-Based Biomarkers to Facilitate Clinical Trial Execution and Interpretation

Henrik Zetterberg, M.D., Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
Roche - Consulting Fees
CogRx - Consulting Fees
Samumed - Consulting Fees

ODFRS2-08-03 Micronutritional biological status and dementia risk

Cécilia Samieri, Ph.D. *has nothing to disclose.*

ODFRS2-08-04 Refining omega-3 supplementation trials in APOE4 carriers for dementia prevention

Hussein N. Yassine, M.D. *has nothing to disclose.*

ODFRS2-09 The value of amyloid PET beyond dichotomization

ODFRS2-09-01 A multi-study analysis of the spatial-temporal progression of amyloid deposition and its utility for longitudinal studies

Isadora Lopes Alves *has nothing to disclose.*

ODFRS2-09-02 Examining Centiloid quantification against visual assessment using [18F]flutemetamol PET

Lyduine Collij, MSc *has nothing to disclose.*

ODFRS2-09-03 Converging evidence for a “gray-zone” of amyloid burden and its relevance

Santiago Bullich *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Life Molecular Imaging GmbH - Salary

ODFRS2-09-04 Emerging beta-amyloid pathology is associated with tau, synaptic, neurodegeneration and gray matter volume differences

Jose Luis Molinuevo, M.D., Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

la Caixa Foundation - Contracted Research

Genentech - Consulting Fees

Biogen - Consulting Fees

Alector - Consulting Fees

Oryzon - Consulting Fees

Lundbeck - Consulting Fees

Janssen - Consulting Fees

GE Healthcare - Consulting Fees

BioCross - Consulting Fees

Roche Diagnostics International Ltd - Consulting Fees

Novartis - Consulting Fees

Lilly - Consulting Fees

Green Valley - Consulting Fees

Eisai - Consulting Fees

Alzheimer's Association (TriBEKa) - Contracted Research

ProMIS Neurosciences - Consulting Fees

MSD - Consulting Fees

ODFRS2-10 Vascular factors of Alzheimer's disease

ODFRS2-10-01 Vascular and Alzheimer's pathology: a mixed affair

Julie A Schneider, M.D., MS *has nothing to disclose.*

ODFRS2-10-02 Vascular risk factors and amyloid pathology: additive or interactive associations?

Jonathan M Schott, M.D. FRCP FMedSci *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Roche - Consulting Fees
Alzheimer's Research UK - Salary
Oxford University Press - Royalty
Biogen - Consulting Fees

ODFRS2-10-03 Novel MRI markers of small vessel disease in relation to Alzheimer's disease

Hilde van den Brink, MSc *has nothing to disclose.*

ODFRS2-10-04 Alzheimer's disease and vascular disease: the clinical spectrum

Christopher Chen, M.D. *has nothing to disclose.*

ODO2-01 Biomarkers (non-neuroimaging): Alzheimer's Disease Incidence, Risk Factors and Biomarkers

ODO2-01-01 Sleep Disturbance and Incident Alzheimer's Disease; a UK Biobank study of 502,538 Middle-Aged to Older Participants

Lei Gao, M.D. *has nothing to disclose.*

ODO2-01-02 Longer and More Frequent Naps Predict Incident Alzheimer's Dementia in Community-Based Older Adults

Peng Li, Ph.D. *has nothing to disclose.*

ODO2-01-03 Early-Mid Adulthood Measures of HDL, Triglycerides and Fasting Glucose are Associated with Late-onset Alzheimer Disease

Xiaoling Zhang, Ph.D. *has nothing to disclose.*

ODO2-01-04 The effect of physical activity on CSF biomarkers of Alzheimer's disease differs between men and women

Marta Milà-Alomà, MSc *has nothing to disclose.*

ODO2-01-05 Plasma YKL40 as a Biomarker for Brain Aging and Injury in Three Community Cohorts

Matthew P Pase, Ph.D. *has nothing to disclose.*

ODO2-02 Biomarkers (non-neuroimaging): Blood Based Biomarkers

ODO2-02-01 Plasma biomarkers predicts amyloid pathology in early-stage Alzheimer's disease

Shieh-Yueh Yang, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

MagQu Co., Ltd. - Salary

ODO2-02-02 Plasma biomarkers predict amyloid pathology in cognitively unimpaired individuals

Anouk den Braber, Ph.D. *has nothing to disclose.*

THIS PRESENTATION IS NOT CME ACCREDITED

ODO2-02-03 Plasma levels of an N-terminal tau fragment are highly associated with future cognitive decline and neurodegeneration in clinically normal elderly

Hyun-Sik Yang, M.D. *has nothing to disclose.*

ODO2-02-04 Tracking neurodegeneration in frontotemporal dementia and Alzheimer's disease: a comparative study of plasma Tau and neurofilament light chain

Julio C. Rojas, M.D., Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
Eli Lilly - Contracted Research

ODO2-02-05 Performances of the plasma A β biomarker in longitudinal data

Akinori Nakamura, M.D., Ph.D. *has nothing to disclose.*

ODO2-02-06 Predicting development of AD clinical symptoms and their progression through a collection of novel plasma A β immunoassays

Lei Liu, M.D., Ph.D. *has nothing to disclose.*

ODO2-03 Biomarkers (non-neuroimaging): EEG and Other Biomarkers

ODO2-03-01 Pronounced regional spectral, connectivity and network changes reflect visual deficits in Posterior Cortical Atrophy: an EEG study on PCA

Casper T. Briels, M.D. *has nothing to disclose.*

ODO2-03-02 Different abnormalities of electroencephalographic (EEG) markers in quiet wakefulness are related to visual hallucinations in patients with Parkinson's and Lewy Body Diseases

Claudio Babiloni *has nothing to disclose.*

ODO2-03-03 EEG: a valuable tool to screen for neurodegeneration in preclinical Alzheimer's disease

Sinead Gaubert, M.D. *has nothing to disclose.*

ODO2-03-04 SELECTIVE LOSS OF EPISODIC MEMORY OF ODOR PERCEPTS IS ASSOCIATED WITH PROGRESSION TO AMNESTIC MCI OR ALZHEIMER'S DISEASE IN COGNITIVELY HEALTHY SENIORS

Mark W Albers, M.D., Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

ADK group - Salary

Partners - Receipt of Intellectual Property Rights/Patent Holder

ADK group - Contracted Research

ODO2-03-05 Characterization of genetic expression patterns in MCI using a multiomics approach and neuroimaging endophenotypes

Apoorva Bharthur Sanjay, M.S *has nothing to disclose.*

ODO2-03-06 Neurofilament light and cognitive performance: associations with amyloid and vascular pathologies in individuals with mild cognitive impairment

Isabelle Bos, Ph.D. *has nothing to disclose.*

ODO2-04 Biomarkers (non-neuroimaging): Longitudinal And Prognostic Biomarker Studies

ODO2-04-01 Cognitive and neurodegenerative profile differences between "Mismatch MCI" (A+T-N+ MCI) and "Prodromal AD" (A+T+N+ MCI) increase with time

Lauren McCollum, M.D. *has nothing to disclose.*

ODO2-04-02 Longitudinal Change in CSF Biomarkers, especially NPTX2, in Non-Demented Elderly Predicts Cognitive Decline and Conversion to Dementia

Denis S Smirnov, BS *has nothing to disclose.*

THIS PRESENTATION IS NOT CME ACCREDITED

ODO2-04-03 Identification of genetic markers linked to accelerated brain volume changes in A β positive population.

Michael Vacher, Ph.D. *has nothing to disclose.*

ODO2-04-04 Cerebrospinal fluid tau biomarkers in the prediction and concordance of neurofibrillary tangle and amyloid pathology

Nicholas J Ashton, Ph.D. *has nothing to disclose.*

ODO2-04-05 Comparison of Cerebrospinal Fluid Phosphorylated Tau 181 and 217 for Cognitive Progression

Michelle M. Mielke, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Biogen - Contracted Research

ODO2-04-06 Cerebrospinal fluid proteomic profiles predict progression to dementia in prodromal AD.

Betty M. Tijms, Ph.D. *has nothing to disclose.*

ODO2-05 Biomarkers (non-neuroimaging): Method Development And Validation

ODO2-05-01 A biorepository for the in-depth validation of pre-analytical sample handling effects on novel blood-based biomarkers for Alzheimer's disease: the first results.

Inge M.W. Verberk, MSc *has nothing to disclose.*

ODO2-05-02 Cerebrospinal fluid biomarker levels are not affected by aspiration or gravity drip extraction methods in Alzheimer's disease, the AIBL study.

James D Doecke, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
Cisro - Salary

ODO2-05-03 Detecting MCI using Real-Time, Ecologically Valid Data Capture Methodology: How to improve Scientific Rigor in Digital Biomarker Analyses

Jiayu Zhou, Ph.D. *has nothing to disclose.*

ODO2-05-04 Using cerebrospinal fluid amyloid-beta₍₁₋₄₂₎ in the memory clinic: concordance with PET and use of biomarker ratios across immunoassays

Eline A.J. Willemse, Ph.D. *has nothing to disclose.*

ODO2-05-05 Association of Plasma Abeta and Tau levels in relation to cognition and brain structure in a diverse community

Charles DeCarli, M.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
Novartis Pharmaceutical - Salary

ODO2-05-06 Transcriptional Endophenotypes Predicting Genetic Risk of Dementia in Mexican Americans

Marcio A Almeida, Ph.D. *has nothing to disclose.*

ODO2-06 Biomarkers (non-neuroimaging): Multimodal Biomarker Studies In Cognitively Unimpaired Cohorts

ODO2-06-01 Orderings of biomarker changes for Alzheimer disease in cognitively normal individuals from 18 to 101 years of age

Chengjie Xiong, Ph.D. *has nothing to disclose.*

ODO2-06-02 Association between cerebrospinal fluid neurofilament light chain and markers of neurofibrillary pathophysiology: Findings from the Knight Alzheimer Disease Research Center

Stephanie A. Schultz, BS *has nothing to disclose.*

ODO2-06-03 Discordant results in CSF/PET A β biomarkers are dependent on APOE genotype and related to inter-individual differences in CSF A β 42, A β 40 and A β 38 isoforms

Arianna Sala, Ph.D. *has nothing to disclose.*

ODO2-06-04 Amyloid- β CSF/PET discordance vs tau load 5 years later: It takes two to tangle

Juhan Reimand, M.D. *has nothing to disclose.*

ODO2-06-05 Serum glial fibrillary acidic protein and neurofilament light as prognostic biomarkers for clinical progression in subjective cognitive decline: the SCIENCE project.

Niels D. Prins, Ph.D., M.D. *has nothing to disclose.*

ODO2-06-06 Plasma phospho-tau181 in over 400 cognitively healthy 69 to 71-year-olds: associations with cerebral amyloid, structural imaging and cognition in the Insight 46 study

Ashvini Keshavan, MRCP Ph.D. *has nothing to disclose.*

ODO2-07 Biomarkers (non-neuroimaging): Novel Biomarkers

ODO2-07-01 Proteomics Identifies CSF Biomarker Panels Reflective of Pathological Networks in the Alzheimer's Disease Brain

Lenora A Higginbotham, M.D. *has nothing to disclose.*

ODO2-07-02 Acute phase markers in CSF reveals inflammatory changes in Alzheimer's disease that are impacted by APOE ϵ 4, sex and age but not pathology

Scott Ayton, Ph.D. *has nothing to disclose.*

ODO2-07-03 Large-scale plasma proteomic analysis identifies proteins and biological pathways associated with incident dementia

Keenan A Walker, Ph.D. *has nothing to disclose.*

ODO2-07-04 Identification of concordant plasma lipid signatures in Alzheimer's disease: Validation between two independent studies of Alzheimer's disease.

Kevin Huynh, Ph.D. *has nothing to disclose.*

ODO2-07-05 Genetic and environmental etiology of AD-related beta-amyloid species, tau & neurofilament light assessed in a middle-aged cohort of male twins.

Nathan A. Gillespie, Ph.D. *has nothing to disclose.*

ODO2-07-06 Undulating changes in human plasma proteome profiles across the lifespan are linked to disease

Benoit Lehallier, Ph.D. *has nothing to disclose.*

ODO2-08 Biomarkers: Searching For Alzheimer's Through The Eyes

ODO2-08-01 Augmenting Cognitive Assessment with Instruction-less Eye-tracking Tests: A Machine Learning Approach for Detecting Abnormal Oculomotor Biomarkers

Kyriaki Mengoudi, MSc *has nothing to disclose.*

ODO2-08-02 Machine learning analysis of speech and eye tracking data to distinguish Alzheimer's clinic patients from healthy controls

Thalia S. Field, M.D., FRCPC, MHSc *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Bayer Canada -
Servier - Consulting Fees

ODO2-08-03 Retinal amyloid deposits found in association with Alzheimer's disease compared with those in age-related macular degeneration

Melanie CW Campbell, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

LumeNeuro - Ownership Interest
University of Waterloo retinal imaging - Receipt of Intellectual Property Rights/Patent Holder

ODO2-08-04 Early tau phosphorylation as a potential retinal biomarker for AD and other tauopathies.

Frederique Jasmine Hart de Ruyter, M.D. *has nothing to disclose.*

ODO2-08-05 Neuroinflammatory processes, A1 astrocyte activation and protein aggregation in the retina of Alzheimer's and Parkinson's Disease patients, possible biomarkers for early diagnosis.

Silvia Di Angelantonio, Ph.D. *has nothing to disclose.*

ODO2-08-06 Retinal Capillary Perfusion in Autosomal Dominant Alzheimer's Disease

Maxwell Singer *has nothing to disclose.*

ODO2-09 Neuroimaging: Earlier Life Risk Factors And Imaging Biomarkers

ODO2-09-01 Cortical thickness and mean diffusivity AD signatures at average age 56 predict 12-year progression to mild cognitive impairment

McKenna E. Williams, MA *has nothing to disclose.*

ODO2-09-02 Mid-life blood pressure and microstructural white matter: findings from the 1946 British birth cohort

Mathew Storey, M.D. *has nothing to disclose.*

ODO2-09-03 Simvastatin maintains white matter integrity in healthy middle-aged adults with increased risk for Alzheimer's disease: a secondary analysis of a randomized controlled trial

Nicholas M Vogt, BA *has nothing to disclose.*

ODO2-09-04 Distinctive Roles of Estrone and Estradiol in Shaping Verbal Memory Circuitry in Postmenopausal Women

Rachel A Schroeder, BS *has nothing to disclose.*

ODO2-09-05 Progression of cerebral small vessel disease in healthy middle-aged adults associated with inherited risk of Alzheimer's disease: the PREVENT-Dementia study

Audrey Low, BSocSci (Hons) *has nothing to disclose.*

ODO2-09-06 Better cardiovascular fitness is associated with better structural brain integrity in midlife: a population-representative birth cohort study

Tracy d'Arbeloff *has nothing to disclose.*

ODO2-10 Neuroimaging: Environmental And Lifestyle Factors - Neuroimaging

ODO2-10-01 Socioeconomic Status Mediates Racial Differences Seen Using the AT(N) Framework

Karin L. Meeker, Ph.D. *has nothing to disclose.*

ODO2-10-02 Associations between ambient air pollution and Alzheimer pathologic change in humans: a secondary analysis of IDEAS study data

Leonardo Iaccarino, Ph.D. *has nothing to disclose.*

ODO2-10-03 Young Adulthood Cardiovascular Risk and MRI and Amyloid PET in Late-Life in a Diverse Cohort: The Kaiser Healthy Aging and Diverse Life Experiences (KHANDLE) Study

Kristen M. George, Ph.D., MPH *has nothing to disclose.*

ODO2-10-04 The relation between accelerometer-derived physical activity and brain structure – findings from the Rhineland Study

Fabienne A.U. Fox, MSc, BSc *has nothing to disclose.*

ODO2-10-05 MRI-Assessed Locus Coeruleus Integrity is Heritable and Associated with Cognition, Alzheimer's Risk, and Sleep-Wake Disturbance

Jeremy A. Elman, Ph.D. *has nothing to disclose.*

ODO2-10-06 Multimodal neuroimaging correlates of NREM and REM sleep EEG spectral power in aging.

Géraldine Rauchs, Ph.D. *has nothing to disclose.*

ODO2-11 Neuroimaging: Imaging Genetics

ODO2-11-01 Genetic markers for brain plasticity

Rachel M Brouwer, Ph.D. *has nothing to disclose.*

ODO2-11-02 Genetic Drivers of Longevity Provide Protection Against Alzheimer's Disease Pathology

Brandalyn C. Riedel, Ph.D. *has nothing to disclose.*

ODO2-11-03 Genome-Wide Association Study of Tau-PET: Association of Variant Near *NTNG2* with Resistance to Tau Deposition

Vijay K Ramanan, M.D., Ph.D. *has nothing to disclose.*

ODO2-11-04 Brain beta-amyloid in twin pairs discordant for episodic memory performance

Eero Vuoksimaa, Ph.D. *has nothing to disclose.*

ODO2-11-05 *BIN1* rs744373 SNP is associated with increased mean diffusivity in non-demented elderly

Anna Rubinski, MSc *has nothing to disclose.*

ODO2-11-06 Polygenic risk score for Alzheimer's disease is related to amyloid positivity in Subjective Cognitive Decline: the SCIENCE project

Sven J. van der Lee, Ph.D. *has nothing to disclose.*

ODO2-12 Neuroimaging: Neuroimaging Predictors Of Cognitive Decline

ODO2-12-01 Synergistic underpinning of global amyloid and cingulate neuroinflammation underlies tau propagation in Alzheimer's disease

Min Su Kang, BSc *has nothing to disclose.*

ODO2-12-02 Predicting factors of cognitive progression in the preclinical-AD:A 5 years follow-up of INSIGHT-Study

Stephanie Bombois, M.D., Ph.D. *has nothing to disclose.*

ODO2-12-03 Amyloid pathology, but not vascular pathology, is associated with risk of incident dementia in non-demented memory clinic participants.

Renée Haan, MSc *has nothing to disclose.*

ODO2-12-04 Amyloid- β deposition in cognitively normal oldest-old is associated with cortical thinning and faster memory decline

Wiesje Pelkmans, MSc *has nothing to disclose.*

ODO2-12-05 Predicting Alzheimer's disease progression: Results from the TADPOLE Challenge

Razvan V Marinescu, Ph.D. *has nothing to disclose.*

ODO2-12-06 *Utility of DTI as a prognostic biomarker in MCI: Beyond AD biomarkers*

SHEELA KUMARI RAGHAVAN PILLAI, Ph.D. *has nothing to disclose.*

ODO2-13 Neuroimaging: Novel Imaging Methods

ODO2-13-01 Grey zone amyloid burden heralds future memory decline: the SCIENCE project

Jarith L. Ebenau, M.D. *has nothing to disclose.*

ODO2-13-02 Evaluation of the novel ¹⁸F-labeled PET tracer SMBT-1 for imaging astrogliosis in healthy elderly controls and A+/T+/(N+) Alzheimer's disease patients

Victor L L Villemagne, M.D. Ph.D. *has nothing to disclose.*

ODO2-13-03 Medial temporal neuroinflammation unleashes tau spreading over the neocortex

Tharick A. Pascoal, M.D., Ph.D. *has nothing to disclose.*

ODO2-13-04 AmyQ: an index to accurately measure cerebral amyloid load

Jordi Pegueroles, MSc *has nothing to disclose.*

ODO2-13-05 Pre-clinical Dose Ranging Efficacy Testing of ADx: A Contrast Agent for Magnetic Resonance Imaging of Amyloid Burden in Alzheimer's Disease

Andrew Badachhape, Ph.D. *has nothing to disclose.*

ODO2-13-06 A Novel MRI Contrast Agent for Identifying Hyperphosphorylated Neurons as a Marker of Future Tau Pathology

Ananth Annapragada, Ph.D. *has nothing to disclose.*

ODO2-14 Neuroimaging: Other Neurodegenerative Disorders

ODO2-14-01 Large Scale, Voxel-to-Voxel Correlation Analysis of Tau Positron Emission Tomography Signal to Histological Pathology in Non-Alzheimer Tauopathies

Yuheng Chen, BA *has nothing to disclose.*

THIS PRESENTATION IS NOT CME ACCREDITED

ODO2-14-02 Developing a novel alpha-synuclein positron emission tomography (PET) tracer for the diagnosis of synucleinopathies

Francesca Capotosti, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

AC Immune SA - Salary

ODO2-14-03 Effect of Disproportionate Enlarged Subarachnoid Space Hydrocephalus (DESH) on Cognition

Petrice M Cogswell, M.D. Ph.D. *has nothing to disclose.*

ODO2-14-04 Predicting the time to tau onset in Down syndrome using amyloid chronicity

Matthew D Zammit, MS *has nothing to disclose.*

ODO2-14-05 The effect of APOE ε4 in Alzheimer's disease biomarkers in Down syndrome

Alexandre Bejanin, Ph.D. *has nothing to disclose.*

ODO2-14-06 Left frontal white matter atrophy links to timing mechanisms relevant for apraxia of speech

Rose Bruffaerts, Ph.D., M.D. *has nothing to disclose.*

ODO2-15 Neuroimaging: Other Neurodegenerative Disorders - Neuroimaging

ODO2-15-01 The evolution of brain atrophy across the disease spectrum of familial frontotemporal dementia

Howard J. Rosen, M.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Wave Neuroscience - Consulting Fees

Ionis Pharmaceuticals - Consulting Fees

Biogen - Contracted Research

ODO2-15-02 ¹⁸F-PI-2620 Tau-PET in Corticobasal Syndrome (ActiGliA cohort)

Matthias Brendel, M.D., MHBA *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

GE healthcare -

Life Molecular Imaging - Consulting Fees

ODO2-15-03 Multimodal imaging markers of tau, neuroinflammation and atrophy to predict clinical progression in progressive supranuclear palsy

Duncan Street, M.D. *has nothing to disclose.*

ODO2-15-04 Connectivity-Based Differentiation of Agrammatic and Logopenic Variants of Primary Progressive Aphasia Using a Whole Brain Data Driven Approach

Lisanne M Jenkins, Ph.D. *has nothing to disclose.*

ODO2-15-05 In vivo assessment of the noradrenergic nucleus Locus Coeruleus in Alzheimer's Disease and other types of Dementia

Filippo Sean Giorgi, M.D., Ph.D. *has nothing to disclose.*

ODO2-15-06 Gray and White Matter Damage Are Associated with Motor Symptoms in Parkinson's Disease

Mahsa Dadar, Ph.D. *has nothing to disclose.*

ODO2-16 Neuroimaging: Sex And Ethnoracial Differences: Biomarkers (Imaging)

ODO2-16-01 Long-term deprivation of ovarian hormones via ovariectomy alters functional connectivity, brain neurochemistry and white matter integrity in a mouse model model of Alzheimer's disease

Firat Kara, Ph.D. *has nothing to disclose.*

ODO2-16-02 The accumulation rate of tau aggregates is higher in females and younger individuals

Ruben Smith, M.D., Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
Alligator Bioscience - Receipt of Intellectual Property Rights/Patent Holder, Salary

ODO2-16-03 Sex-associated differences in pathology burden in early-onset Alzheimer's disease

Jenna Rae Groh, BA *has nothing to disclose.*

ODO2-16-04 ApoE4 Packs A Punch in Women: Sex-Specific Vulnerability for Tau and Neuroinflammation

Yi-Ting Wang, MSc *has nothing to disclose.*

ODO2-16-05 Association between race/ethnicity and neuroimaging biomarkers in middle- and older-aged adults

Indira C Turney, Ph.D. *has nothing to disclose.*

ODO2-16-06 Race and sex differences in midlife changes in cerebral volume and perfusion

Justine E Moonen, M.D., Ph.D. *has nothing to disclose.*

ODO2-17 Neuroimaging: The Medial Temporal Lobe In 2020

ODO2-17-01 Hippocampal-retrosplenial connectivity is associated with tau pathology and memory in cognitively normal older adults

Jacob Ziontz, BA *has nothing to disclose.*

ODO2-17-02 Medial temporal lobe hyperactivity during memory processing in older adults is associated with entorhinal tau deposition

Jenna N. Adams, BA *has nothing to disclose.*

ODO2-17-03 Longitudinal hippocampal atrophy is associated with an amyloid-independent entorhinal tauopathy and an amyloid-dependent neocortical tauopathy

Bernard Hanseeuw, M.D., Ph.D. *has nothing to disclose.*

ODO2-17-04 Novel ex vivo MRI atlas of the medial temporal lobe can be used to characterize structural changes due to Alzheimer's Disease pathology

Sadhana Ravikumar *has nothing to disclose.*

ODO2-17-05 Hippocampal subfield volume differences are independent of age in teenagers and young adults with Down syndrome

Katherine A Koenig, Ph.D. *has nothing to disclose.*

ODO2-17-06 Tau pathology mediates age effects on medial temporal lobe atrophy

Laura Wisse *has nothing to disclose.*

ODO2-18 Neuroimaging: Understanding Tau Progression

ODO2-18-01 Predicting future regional tau accumulation in preclinical Alzheimer's disease

Joseph Giorgio *has nothing to disclose.*

ODO2-18-02 Spatiotemporal imaging phenotypes of tau pathology in Alzheimer's disease

Neil P. Oxtoby, Ph.D. *has nothing to disclose.*

THIS PRESENTATION IS NOT CME ACCREDITED

ODO2-18-03 Longitudinal flortaucipir accumulation is spatially distinct across baseline tau burden stages: Summary from three phase 2/3 interventional trials in Alzheimer's disease

Sergey Shcherbinin, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eli Lilly and Company - Ownership Interest, Salary

ODO2-18-04 Heterogeneous distribution of tau pathology in the behavioral variant of Alzheimer's disease

Ellen H. Singleton, MSc *has nothing to disclose.*

ODO2-18-05 Tau-first subtype of Alzheimer's disease progression consistently identified through PET and CSF

Leon M Aksman, Ph.D. *has nothing to disclose.*

ODO2-18-06 Predicting future rates of tau accumulation on PET

Clifford R. Jack, M.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

1. Roche 2. Eisai -

SFRS2-01 Strategic roadmap for the translation of tau biomarkers in the clinic: an international task force

SFRS2-01-01 Alzheimer's Disease Biomarker Roadmap 2020: time for tau

Alessandra Dodich, Ph.D. *has nothing to disclose.*

SFRS2-01-02 Alzheimer's Disease Biomarker Roadmap 2020: [¹⁸F]flortaucipir

Valentina Garibotto, M.D. *has nothing to disclose.*

SFRS2-01-03 Alzheimer's Disease Biomarker Roadmap 2020: second-generation tau PET tracers

Gerard N Bischof, Ph.D. *has nothing to disclose.*

SFRS2-01-04 Alzheimer's Disease Biomarker Roadmap 2020: fluids biomarkers

Antoine Leuzy, Ph.D. *has nothing to disclose.*

SO2-01 Neuroimaging: Imaging The Human Synapse In AD

SO2-01-01 Association between Cerebral Amyloid Accumulation and Synaptic Density in Alzheimer's Disease: A Multitracer PET Study

Ryan S. O'Dell, M.D., Ph.D. *has nothing to disclose.*

SO2-01-02 Regional tau pathology is associated with loss of synapses and reduced synaptic activity: a combined [¹⁸F]flortaucipir, [¹¹C]UCB-J and magnetoencephalography study

Emma M. Coomans, MSc *has nothing to disclose.*

CME CREDIT APPROVAL PENDING

SO2-01-03 Microglial activation indexed by [¹¹C]PBR28 is associated with synaptic depletion in the Alzheimer's disease spectrum.

Joseph Therriault, BSc *has nothing to disclose.*

SO2-01-04 Untangling the roles of amyloid and tau in synaptic and axonal loss in the course of Alzheimer's disease

Joana B. Pereira, Ph.D. *has nothing to disclose.*

SO2-01-05 ICA-derived sources of synaptic density PET ([¹¹C]UCB-J) relate to cognitive impairment severity in Alzheimer's disease

Xiaotian T. Fang, Ph.D. *has nothing to disclose.*

SO2-01-06 SNAP25 reflects amyloid- and tau-related synaptic damage: associations between PET, VBM and cerebrospinal fluid biomarkers of synaptic dysfunction in the Alzheimer's disease spectrum

Andréa Lessa Benedet, Ph.D. *has nothing to disclose.*

SO2-03 Developing Topic Session: Biomarkers

SO2-03-01 Quantification of Neurological Blood Based Biomarkers in Critically Ill Patients with COVID-19

Jennifer Cooper, BMLSc *has nothing to disclose.*

SO2-03-02 Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to *post-mortem* and improves the clinical characterisation of cognitive decline

Juan Lantero Rodriguez, MSc *has nothing to disclose.*

SO2-03-03 Longitudinal changes in established and exploratory cerebrospinal fluid biomarkers by pTau/Aβ₄₂ status in cognitively unimpaired adults.

Carol A Van Hulle, Ph.D. *has nothing to disclose.*

THIS PRESENTATION IS NOT CME ACCREDITED

SO2-03-04 Exploring molecular biomarkers with potential prognostic value in longitudinal observational studies on Alzheimer's disease

Eugeen Vanmechelen, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

ADx NeuroSciences –

SO2-03-05 Imaging Misfolded Tau in the Retina

Umur A. Kayabasi, M.D. *has nothing to disclose.*

SO2-03-06 Sleep duration genes associated with cognition across the adult age-range

Angeliki Tsapanou, Ph.D. *has nothing to disclose.*

SFRS2-02 Neurobiological subtypes of Alzheimer's disease

SFRS2-02-01 Neuropathologically-defined subtypes of Alzheimer's disease

Melissa E Murray, Ph.D. *has nothing to disclose.*

SFRS2-02-02 Disentangling neurodegeneration subtypes of Alzheimer's disease using data-driven methods

Michel J. Grothe, Ph.D. *has nothing to disclose.*

SFRS2-02-03 Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics

Betty M. Tijms, Ph.D. *has nothing to disclose.*

SFRS2-02-04 A conceptual framework for future studies on subtypes of Alzheimer's disease

Daniel Ferreira, Ph.D. *has nothing to disclose.*

SFRS2-03 The role of microglia activation in the development of amyloid and tau pathology in Alzheimer's disease

SFRS2-03-01 Higher TREM2 levels and microglia activation associated with slower rates of amyloid PET increase in humans and a transgenic mouse model of beta-amyloid.

Michael Ewers, Ph.D. *has nothing to disclose.*

SFRS2-03-02 Innate immune activation of the NLRP3 inflammasome pathway drives tau pathology

Christina Ising, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
C2N Diagnostics - Royalty

SFRS2-03-03 Neuroinflammation imposes vulnerability to tau propagation

Pedro Rosa-Neto, M.D., Ph.D. *has nothing to disclose.*

SFRS2-03-04 The prognostic role of microglia and tau PET in Alzheimer's Disease

Maura Malpetti, MSc *has nothing to disclose.*

SSYM2-01 Towards A Precision Medicine Approach in Alzheimer's Disease

SSYM2-01-01 Blood-Based Biomarkers To Predict Current And Future Alzheimer's disease

Randall J Bateman, M.D., Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Hoffman La-Roche/Genentech - Consulting Fees, Contracted Research
C2N Diagnostics - Ownership Interest
Tau Silk Consortium -
Eli Lilly & Co - Contracted Research
Avid Radiopharmaceuticals - Contracted Research
Janssen - Contracted Research
DIAN-TU Pharma Consortium -

SSYM2-01-02 Accurate Prediction of β -Amyloid Positivity Using Risk Models and Plasma A β And P-tau Analyses

Sebastian Palmqvist, M.D., Ph.D. *has nothing to disclose.*

SSYM2-01-03 Biomarker-Based Prognosis For People With Mild Cognitive Impairment

Ingrid S. van Maurik, MSc *has nothing to disclose.*

SSYM2-01-04 Organizing Mechanistic Knowledge About Neurodegenerative Diseases For The Improvement Of Drug Development And Therapy

Martin Hofmann-Apitius *has nothing to disclose.*

SFRS2-04 Clinical study results of AD blood biomarkers.

SFRS2-04-01 Mass spectrometry measures of plasma A β , tau and p-tau isoforms relationship to amyloid PET, tau PET, and clinical stage of Alzheimer's disease

Suzanne E Schindler, M.D., Ph.D. *has nothing to disclose.*

SFRS2-04-02 Plasma p-tau immunoassays, methodological aspects and clinical performance

Kaj Blennow, M.D., Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Biogen - Consulting Fees
Novartis - Consulting Fees
Axon Neuroscience - Consulting Fees
MagQu - Consulting Fees
Abcam - Consulting Fees
Roche - Consulting Fees

SFRS2-04-03 Phospho-tau217 and phospho-tau181 in plasma and CSF as biomarkers for Alzheimer's disease

Oskar Hansson *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
Biogen - Consulting Fees

SFRS2-04-04 Amyloid, pTau, NfL, and GFAP as biomarkers for Alzheimer's disease

Elisabeth H Thijssen, MSc *has nothing to disclose.*

SSYM2-02 Measuring Tau Accumulation And Progression

SSYM2-02-01 Tau Progression Evidence From Tau PET Imaging

Rik Ossenkoppele, Ph.D. *has nothing to disclose.*

SSYM2-02-02 Pathologic Progression Of Tau

Gabor G. Kovacs, M.D. Ph.D. FRCPC *has nothing to disclose.*

SSYM2-02-03 Multi-omic Approach To Tau Accumulation And Progression

Philip L De Jager, M.D.,Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
Biogen - Contracted Research, Consulting Fees
Roche - Contracted Research

SSYM2-02-04 Interaction Of Tau With Other Pathologies

Virginia M-Y Lee, Ph.D. *has nothing to disclose.*

SFRS2-05 Tau and Memory in the Temporal Lobe: Insights into the beginning of Alzheimer's disease

SFRS2-05-01 Functional neuroanatomy of episodic memory in the human brain

Anne Maass, Ph.D. *has nothing to disclose.*

SFRS2-05-02 Tau, neural function, and episodic memory in the medial temporal lobe

David Berron, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
neotiv GmbH - Ownership Interest

SFRS2-05-03 Tracking the origin of tau spread in the brain

Heidi IL Jacobs, Ph.D. *has nothing to disclose.*

SFRS2-05-04 Tau spreads through episodic memory networks in the aging brain

William J. Jagust, M.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Optoceutics - Ownership Interest

Genentech - Consulting Fees

Novartis - Consulting Fees

Bioclinica - Consulting Fees

Grifols - Consulting Fees

SFTS2-01 LEADS: Sporadic Early-Onset Alzheimer's Disease in the Spotlight

SFTS2-01-01 Study design and clinical characteristics of the LEADS cohort

Liana G. Apostolova, M.D., MS *has nothing to disclose.*

SFTS2-01-02 Amyloid and tau PET in sporadic early-onset Alzheimer's Disease: preliminary results from LEADS

Gil D. Rabinovici, M.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Life Molecular Imaging - Contracted Research

Eisai - Consulting Fees

GE Healthcare - Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agent

Avid Radiopharmaceuticals - Contracted Research

Eli Lilly - Contracted Research

SFTS2-01-03 MRI measures of neurodegeneration in the LEADS cohort

Brad C. Dickerson, M.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Lilly - Consulting Fees

Biogen - Consulting Fees

Merck - Consulting Fees

Arkuda - Consulting Fees

SFTS2-01-04 Examining Early-onset and late-onset Alzheimer's disease (EOAD) to understand the neuropathological substract of typical and atypical AD

Lea Tenenholz Grinberg, M.D., Ph.D. *has nothing to disclose.*

SO2-02 Biomarkers: Leveraging Postmortem Collections To Validate Neuroimaging

SO2-02-01 TAUOPATHY IN AUTOSOMAL DOMINANT AND LATE-ONSET ALZHEIMER DISEASE

Charles Chen *has nothing to disclose.*

SO2-02-02 [¹⁸F]Flortaucipir PET to autopsy pathology comparisons in Alzheimer's disease and other neurodegenerative diseases

David N. Soleimani-Meigooni, M.D. *has nothing to disclose.*

SO2-02-03 High-resolution postmortem MRI reveals TDP-43 association with medial temporal lobe subregional atrophy

Paul A. Yushkevich, Ph.D. *has nothing to disclose.*

CME CREDIT APPROVAL PENDING

SO2-02-04 Neuropathological Diagnoses of Subjects Autopsied in the Phase 3 Clinicopathological Study of Flortaucipir F18 PET Imaging

Thomas G Beach, M.D., Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Prothena Biosciences - Consulting Fees

Banner Health - Salary

Vivid Genomics - Ownership Interest, Consulting Fees

SO2-02-05 Alpha-frequency synchronization deficits during life predict postmortem neurofibrillary tangle burden in Alzheimer's disease.

Kamalini G Ranasinghe, M.D. Ph.D. *has nothing to disclose.*

SO2-02-06 Dementia is strongly associated with atrophy of Medial Temporal Lobe structures even after accounting for neuropathologies

Davis C. Woodworth, Ph.D. *has nothing to disclose.*

Wednesday, July 29, 2020, AAIC Disclosures

12:00 a.m. — 11:59 p.m. Central Daylight Time (North America)

ODFRS3-01 An update on the pathological, imaging and clinical features underlying heterogeneity across individuals with Alzheimer's disease.

ODFRS3-01-01 Cognitively-defined subtypes of Alzheimer's disease

Paul K Crane, M.D., MPH *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Viiv - Consulting Fees

Gilead - Consulting Fees

ODFRS3-01-02 Progressive Dysexecutive Syndrome Due to Alzheimer's Disease: A Description of 55 Cases and Comparisons to other Clinical AD Phenotypes

David T Jones, M.D. *has nothing to disclose.*

ODFRS3-01-03 How "atypical" is the neuroimaging signature of Alzheimer's atypical variants? MRI and PET imaging of Posterior Cortical Atrophy and logopenic variant of Primary Progressive Aphasia

Renaud La Joie, Ph.D. *has nothing to disclose.*

ODFRS3-01-04 A novel type of amyloid-beta plaques identified in early-onset AD

baayla D.C. boon, M.D. *has nothing to disclose.*

ODFRS3-02 Examining subjective cognitive decline in diverse, ethnoracial populations

ODFRS3-02-01 Subjective Cognitive Impairment Differs by Racial/Ethnic Groups and Socio-Demographic Factors – The Multi-Ethnic Study of Atherosclerosis and Alzheimer's Disease (MESA-MIND)

Timothy M. Hughes, Ph.D., MPH *has nothing to disclose.*

ODFRS3-02-02 Differences in the characteristics, neuropsychiatric comorbidities, and psychometric features of subjective cognitive decline in Hispanics versus Non-Hispanic Whites

Arline Faustin, M.D. *has nothing to disclose.*

ODFRS3-02-03 Characterization of Subjective Cognitive Concerns (SCC) in a Racially/Ethnically Diverse Community Based Elderly Cohort: Results from the Einstein Aging Study (EAS)

Mindy J. Katz, MPH *has nothing to disclose.*

ODFRS3-02-04 Gender differences in the perception of subjective vs. objective cognitive decline – baseline data from the SCD-Well trial

Dix U. Meiberth, M.Sc. *has nothing to disclose.*

ODFRS3-03 Examining Subjective Cognitive Decline through an Interdisciplinary Lens

ODFRS3-03-01 Differences in everyday cognitive difficulties in demographically-diverse community dwelling older adults using daily diaries: A comparison among older adults with and without SCD

Jacqueline Mogle, Ph.D. *has nothing to disclose.*

ODFRS3-03-02 Subjective cognitive decline is associated with longitudinal cerebral blood flow reductions and gray matter atrophy in older adults

Katherine A. Gifford, PsyD *has nothing to disclose.*

ODFRS3-03-03 Subjective Cognitive Decline Predicts Progression to Dementia in a Multiracial Community Sample

Silvia Chapman, Ph.D. *has nothing to disclose.*

ODFRS3-03-04 Higher perceived age-related gains and losses relate to lower objective cognitive scores

Serena Sabatini, MSc *has nothing to disclose.*

ODFRS3-04 Interventions targeting the noradrenergic system in Alzheimer's and neurodegenerative disease

ODFRS3-04-01 Transcutaneous vagus nerve stimulation increases locus coeruleus function and memory performance in older individuals

Heidi I.L. Jacobs, Ph.D. *has nothing to disclose.*

ODFRS3-04-02 Transcutaneous vagal nerve stimulation effects on the salience network in patients with amnesic mild cognitive impairment

John B Williamson, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
Evren Technologies - Ownership Interest

ODFRS3-04-03 Noradrenergic contributions to cognitive decline and treatment potential in Progressive Supranuclear Palsy and Parkinson's disease

James B Rowe, M.D. Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
Biogen - Consulting Fees
Lilly -
AZ -
Janssen -
Asceneuron - Consulting Fees
UCB - Consulting Fees

ODFRS3-04-04 Amyloid β redirects norepinephrine signaling to activate the pathogenic GSK3 β /tau cascade

Qin Wang, M.D., Ph.D. *has nothing to disclose.*

ODFRS3-06 Tau Therapies: From Mouse to Molecule

THIS PRESENTATION IS NOT CME ACCREDITED

ODFRS3-06-01 Key Developmental Milestones for Tau Therapeutics

Jeffrey L. Cummings, M.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Probiogrug - Consulting Fees
Nutricia - Consulting Fees
Hisun - Consulting Fees
Foresight - Consulting Fees
Cortexyme - Consulting Fees
Cerevel - Consulting Fees
Biogen - Consulting Fees
Avanir - Consulting Fees
Third Rock - Consulting Fees
ADAMAS - Ownership Interest
Signant health - Consulting Fees
Roche - Consulting Fees
QR Pharma - Ownership Interest
Otsuka - Consulting Fees
MedAvante - Ownership Interest
Grifols - Consulting Fees
Eisai - Consulting Fees
Cognoptix - Consulting Fees
Cerecin - Consulting Fees
BioAsis - Ownership Interest
Suven - Consulting Fees
Alzheon - Consulting Fees
Actinogen - Consulting Fees
Samus Therapeutics - Consulting Fees
Resverlogix - Consulting Fees
QR - Consulting Fees
Orion - Consulting Fees
Idorsia - Consulting Fees
Green Valley - Consulting Fees
EIP Pharma - Consulting Fees
CNS Innovations - Ownership Interest
Cassava - Consulting Fees
Axsome - Consulting Fees
United neuroscience - Ownership Interest, Consulting Fees
Sunovion - Consulting Fees
Alkahest - Consulting Fees
Acadia - Consulting Fees
Samumed - Consulting Fees
ReMYND - Consulting Fees

ODFRS3-06-03 Validity of Tau as both a biomarker and target for AD and the dynamics of tau over the course of the disease

Nicolas R Barthelemy, Ph.D. *has nothing to disclose.*

CME CREDIT APPROVAL PENDING

ODFRS3-06-04 Tau Therapeutics: Clinical Development Status and Future Directions

Adam L. Boxer, M.D., Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Sangamo - Consulting Fees
Pinteon - Consulting Fees
Lundbeck - Consulting Fees
Biogen - Contracted Research
Arvinas - Ownership Interest
Abbvie - Consulting Fees
UCB - Consulting Fees
Samumed - Consulting Fees
Passage Bio - Consulting Fees
Ionis - Consulting Fees
Bioage - Consulting Fees
Arkuda - Ownership Interest
Third Rock - Consulting Fees
Roche - Contracted Research
Novartis -
Eisai - Contracted Research
Asceneuron - Consulting Fees
Alector - Ownership Interest

ODFRS3-07 The Conduct of Clinical Investigations in the Down Syndrome Population

ODFRS3-07-01 Engaging the Down Syndrome Community: Overcoming Barriers to Clinical Trial Recruitment

James A Hendrix, Ph.D. *has nothing to disclose.*

ODFRS3-07-02 Biomarkers and Trial-Ready Cohorts for Alzheimer's disease Clinical Trials in the Down Syndrome Population

Juan Fortea, M.D. Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

AC Inmune - Consulting Fees
Novartis - Consulting Fees

ODFRS3-07-03 Cognitive and Clinical Outcome Measures for Alzheimer's disease prevention trials in adults with Down Syndrome

Andre Strydom, M.D., Ph.D. *has nothing to disclose.*

THIS PRESENTATION IS NOT CME ACCREDITED

ODFRS3-07-04 Functional Considerations in the Conduct of Clinical Investigations in the Adult Down Syndrome Population

Joanne M Bell, MA, Ph.D. *has nothing to disclose.*

ODFRS3-08 Results of the DIAN-TU Prevention Trial of Solanezumab and Gantenerumab in Dominantly Inherited AD (pre-recorded material)

THIS PRESENTATION IS NOT CME ACCREDITED

ODFRS3-08-01 Overview of dominantly inherited AD and top-line DIAN-TU results of solanezumab and gantenerumab

Randall J Bateman, M.D., Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

C2N Diagnostics - Ownership Interest

Tau Silk Consortium -

Eli Lilly & Co - Contracted Research

Avid Radiopharmaceuticals - Contracted Research

Janssen - Contracted Research

DIAN-TU Pharma Consortium -

Hoffman La-Roche/Genentech - Contracted Research, Consulting Fees

ODFRS3-08-02 Solanezumab In-depth Outcomes

Martin R. Farlow, M.D. *has nothing to disclose.*

CME CREDIT APPROVAL PENDING

ODFRS3-08-03 Gantnerumab In-depth Outcomes

Stephen P. Salloway, M.D. *has nothing to disclose.*

ODO3-01 Clinical Manifestations: Language Markers Of Early Disease

ODO3-01-01 Novel metrics of semantic fluency as preclinical markers of cognitive impairment

Jet MJ Vonk, Ph.D. *has nothing to disclose.*

ODO3-01-02 Engagement in social activities is related to connected speech and language outcomes in the Wisconsin Registry for Alzheimer's Prevention

Kimberly D Mueller, MS, Ph.D. *has nothing to disclose.*

ODO3-01-03 Duration of Verbal Fluency Inter-word Intervals and Risk of Cognitive Impairment

David G. Clark, M.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

UpToDate - Royalty

ODO3-01-04 Perception of Fragmented Letters Differentiates Pathologically Confirmed Dementia with Lewy Bodies from Alzheimer's Disease

David P. Salmon, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Aptinyx Inc - Consulting Fees

Biogen Inc - Consulting Fees

ODO3-01-05 Illiteracy and Risk of Mild Cognitive Impairment among Mexican Older Adults: Data from the Mexican Health and Aging Study (MHAS)

Miguel Arce Rentería, Ph.D. *has nothing to disclose.*

ODO3-01-06 Development and validation of composite scores for language and visuospatial functioning in ADNI

Seo-Eun Choi, Ph.D. *has nothing to disclose.*

ODO3-02 Clinical Manifestations: Update On Pharmacologic And Nonpharmacologic Interventions

CME CREDIT APPROVAL PENDING

ODO3-02-01 Long-term treatment with cholinesterase inhibitors in Alzheimer's disease is associated with modest but persisting benefits on cognition and reduced mortality

Maria Eriksson, M.D., Ph.D., Prof. *has nothing to disclose.*

ODO3-02-02 Relationships between oral hypoglycemic drugs and memory decline in people with type 2 diabetes: a stratified longitudinal observational study

Che-Yuan Wu, HBSch *has nothing to disclose.*

THIS PRESENTATION IS NOT CME ACCREDITED

ODO3-02-03 Vafidemstat in mild to moderate Alzheimer's disease: The ETHERAL study European cohort interim analysis

Roger Alan Bullock, M.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Oryzon Genomics - Salary

Alzheimer's Association International Conference® 2020

ODO3-02-04 Combined training of aerobic exercise and 3D video game to improve hippocampal and memory functions in older adults : A RCT trial

Juan Li, Ph.D. *has nothing to disclose.*

ODO3-02-05 A Randomized Control Trial of Activity Scheduling to Reduce the Impact of the Caring Role on Older Adults with Dementia

Frank Ho-yin Lai, Ph.D. *has nothing to disclose.*

ODO3-02-06 Complementary analyses of the AMBAR Trial: impact of discontinuations, consistency of results across outcomes and additional adjustments

Suzanne B. Hendrix, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
Grifols - Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agent

ODO3-03 Drug Development: Clinical Trial Design and Implementation

ODO3-03-01 The Alzheimer's Prevention Initiative Generation Program: a global perspective on best practices for site support and engagement to accelerate participant recruitment

Trisha L Walsh, MSW *has nothing to disclose.*

ODO3-03-02 Alternatives to MMRM for Preclinical Alzheimer's Clinical Trials

Michael C Donohue, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
Roche - Consulting Fees
Biogen - Consulting Fees
Janssen - Salary, Ownership Interest

ODO3-03-03 Preliminary Results from The Study Partner Availability Limitations Study (PALS)

Emily A. Largent, JD. Ph.D., RN *has nothing to disclose.*

ODO3-03-04 Utilizing a Mobile Clinical Trials Unit: Lessons Learned from the First Three Years

Amanda G Smith, M.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
Novartis - Contracted Research
Eli Lilly - Contracted Research
Biogen - Contracted Research
NeuroEM - Contracted Research
Eisai - Consulting Fees, Contracted Research
AbbVie - Contracted Research
Suven - Contracted Research
Miro - Contracted Research
Biohaven - Contracted Research

ODO3-03-05 AHEAD 3-45 Study Design: A Global Study to Evaluate Efficacy and Safety of Treatment with BAN2401 for 216 weeks in Preclinical Alzheimer's Disease With Intermediate Amyloid (A3 Trial) and Elevated Amyloid (A45 Trial)

Paul S Aisen, M.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Merck - Consulting Fees

Eisai - Contracted Research

Samus - Consulting Fees

Lilly - Contracted Research

Biogen - Consulting Fees

Roche - Consulting Fees

ImmunoBrain Checkpoint - Consulting Fees

THIS PRESENTATION IS NOT CME ACCREDITED

ODO3-03-06 The PIONEER Study: A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 2 Trial of the Effects of T3D-959 on Safety, Cognition, Function and Plasma Biomarkers in Mild to Moderate Alzheimer's Disease Subjects: Rationale and Study Design

John Didsbury, Ph.D. *has nothing to disclose.*

ODO3-04 Drug Development: Preclinical Small Molecule Drug Discovery

THIS PRESENTATION IS NOT CME ACCREDITED

ODO3-04-01 In vivo validation of a lead compound targeting tau self-association in two mouse models of tauopathy

James G. Moe, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Oligomerix, Inc. - Salary

CME CREDIT APPROVAL PENDING

ODO3-04-02 Cellulose ethers reduce amyloid-beta pathology in *in vitro* and *in vivo* Alzheimer's disease model

Tahir Ali, Ph.D. *has nothing to disclose.*

ODO3-04-03 Aquaporin4 Facilitator decrease insoluble amyloid b of 5xFAD mouse brain

Ingrid L. Kwee, M.D. *has nothing to disclose.*

ODO3-04-04 Taxifolin is a novel therapeutic agent for Alzheimer's disease and cerebral amyloid angiopathy

Satoshi Saito, M.D.,Ph.D. *has nothing to disclose.*

ODO3-04-05 Novel small chemical compound with NFAT modulatory properties alleviates synaptic dysfunction and improves cognition in mouse models of amyloid pathology

Christopher M. Norris, Ph.D. *has nothing to disclose.*

CME CREDIT APPROVAL PENDING

ODO3-04-06 ELUCIDATING EMERGING THERAPEUTICS: P75 RECEPTOR MODULATION REVERTS TAUOPATHY ASSOCIATED ALTERATIONS IN SYNAPSE-RELEVANT GENE EXPRESSION SIGNATURES

Amira Latif-Hernandez, Ph.D. *has nothing to disclose.*

ODO3-05 Human: Improving Clinical Trial Methodology

ODO3-05-01 Success of referring participants to the Generation Program and lessons learned for future enrollment into Alzheimer's disease prevention trials

David Gordon, MS *has nothing to disclose.*

ODO3-05-02 Combining Evidence Across Multiple Endpoints with a Global Statistical Test: Comparison of Z-scores Versus Ranks

Samuel P Dickson, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
Pentara Corporation - Salary

ODO3-05-03 T2 Protect AD: Achieving a Rapid Recruitment Timeline in a Multi-Site Clinical Trial for Individuals with Mild-to-Moderate Alzheimer's Disease

Andrea Z. LaCroix, Ph.D. *has nothing to disclose.*

ODO3-05-04 The electronic Person-Specific Outcome Measure (ePSOM) development programme: Overall approach

Stina Saunders, MA, MRes *has nothing to disclose.*

THIS PRESENTATION IS NOT CME ACCREDITED

ODO3-05-05 Baseline Characteristics from TANGO: Phase 2 Study to Evaluate gosuranemab (BIIB092) in Patients with Early Alzheimer's Disease

Elena Ratti, M.D., MMSc *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
Biogen - Salary

CME CREDIT APPROVAL PENDING

ODO3-05-06 Is It Time to Use Predictive Models to Boost Power of Alzheimer's Disease Clinical Trials? A Post-Hoc Analysis of Phase 3 Solanezumab Trials.

Ali Ezzati, M.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eisai - Consulting Fees

ODO3-06 Human: Putative Therapeutic Results For Alzheimer's And Related Dementias

THIS PRESENTATION IS NOT CME ACCREDITED

ODO3-06-01 Evaluation of the Efficacy and Safety of Orally Administered BI 425809 During a 12-Week Treatment Period Compared with Placebo in Patients with Cognitive Impairment Due to Alzheimer's Disease

Glen Wunderlich, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Boehringer Ingelheim (Canada) Ltd - Salary

THIS PRESENTATION IS NOT CME ACCREDITED

ODO3-06-02 HARMONY: Response to Pimavanserin in the 12-Week, Open-label Treatment Phase

Erin P. Foff, M.D., Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

ACADIA Pharmaceuticals, Inc. - Salary

THIS PRESENTATION IS NOT CME ACCREDITED

ODO3-06-03 AL001 restores CSF PGRN levels and normalizes disease-associated biomarkers in individuals with frontotemporal dementia due to heterozygous mutations in the progranulin gene

Robert Paul, M.D., Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Alector - Ownership Interest

CME CREDIT APPROVAL PENDING

ODO3-06-04 ACI-24 Vaccine in Adults with Down Syndrome

Michael S Rafii, M.D., Ph.D. *has nothing to disclose.*

CME CREDIT APPROVAL PENDING

ODO3-06-05 TNF- α INHIBITORS IN PREVENTING MILD COGNITIVE IMPAIRMENT (MCI), DEMENTIA, AND ALZHEIMER'S DISEASE (AD): AN UPDATED RETROSPECTIVE REVIEW USING BOTH EMR AND CLAIMS DATA

Jennifer L Stacey, BS *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

TriNetX - Salary

CME CREDIT APPROVAL PENDING

ODO3-06-06 Effects of Candesartan vs. Lisinopril on Neurocognitive Functioning in Executive Mild Cognitive Impairment: The CALIBREX Trial

Ihab Hajjar, M.D., MS *has nothing to disclose.*

ODO3-07 Neuropsychiatry and Behavioral Neurology: Neuropsychiatric Symptoms In MCI And Dementia

ODO3-07-01 Neuropsychiatric symptoms and cognitive trajectories in older adults free of dementia: The Mayo Clinic Study of Aging

Janina Krell-Roesch, Ph.D. *has nothing to disclose.*

ODO3-07-02 Pharmacological treatment of neuropsychiatric symptoms of dementia: a systematic review and network meta-analysis

Yu-Yuan Huang, M.D., Ph.D. *has nothing to disclose.*

ODO3-07-03 Evolution of unawareness of memory decline in individuals with autosomal dominant Alzheimer's disease.

Patrizia Vannini, Ph.D. *has nothing to disclose.*

ODO3-07-04 Social cognitive abilities in older adults with mild cognitive impairment and dementia

Russell J Chander, BA *has nothing to disclose.*

ODO3-07-05 CHARACTERISING MILD BEHAVIOURAL IMPAIRMENT IN ASIAN MILD COGNITIVE IMPAIRMENT AND COGNITIVELY NORMAL INDIVIDUALS

Fennie Wong, BSocSci *has nothing to disclose.*

ODO3-07-06 Neuropsychiatric Abnormalities in Familial Frontotemporal Dementia: Findings from the LEFFTDS Cohort

Leah K Forsberg, Ph.D. *has nothing to disclose.*

ODO3-08 Neuropsychiatry and Behavioral Neurology: Novel Risk Factors And Novel Approaches To Risk In Dementia

ODO3-08-01 The impact of hearing loss on cognitive decline and risk of progression to mild cognitive impairment in healthy adults

Magda Bucholc, Ph.D. *has nothing to disclose.*

ODO3-08-02 Low plasma cortisol and large hippocampal volume are associated with reduced risk of clinical progression in MCI

Miranka Wirth, Ph.D. *has nothing to disclose.*

ODO3-08-03 Association of Late-onset Dementia risk scores and Alzheimer's disease pathology status in preclinical older adults

Chinedu T Udeh-Momoh, Ph.D. *has nothing to disclose.*

ODO3-08-04 Abnormal brain structure mediates the association between ApoE4 and slow gait among patients with pathological cognitive impairment: Results from the Ontario Neurodegenerative Research Initiative

Manuel Montero-Odasso, M.D., Ph.D. *has nothing to disclose.*

ODO3-08-05 Diastolic Dysfunction and Cognitive Impairment

Alicia S Parker, M.D. *has nothing to disclose.*

ODO3-08-06 Divergent effects of education and occupation history on age at onset within Alzheimer's and frontotemporal dementia

Zachary A. Miller, M.D. *has nothing to disclose.*

ODO3-09 Neuropsychiatry and Behavioral Neurology: The Neuropsychiatry Of Subjective Cognitive Disorder And Prodromal AD

ODO3-09-01 Dynamic network connectivity alteration predicts cognitive decline in Alzheimer's disease spectrum

Qing Wang, Ph.D. *has nothing to disclose.*

ODO3-09-02 Reflective pondering is associated with a global cognitive marker of Alzheimer's Disease risk.

Harriet Demnitz-King, MSc *has nothing to disclose.*

ODO3-09-03 Robot-assisted detection of subclinical dementia: progress report and preliminary findings.

Krister Håkansson, Ph.D. *has nothing to disclose.*

ODO3-09-04 Subjective cognitive decline, anxiety symptoms, and the risk of mild cognitive impairment and dementia

Tau Ming Liew, MRCPsych, Ph.D. *has nothing to disclose.*

ODO3-09-05 Amyloid positive individuals with subjective cognitive decline present increased CSF neurofilament light levels that relates to hippocampal volume

Gonzalo Sánchez-Benavides, Ph.D. *has nothing to disclose.*

ODO3-09-06 Identifying and predicting heterogeneity in cognitive decline among individuals with prodromal Alzheimer's disease using a latent class analysis

Roos J. Jutten, Ph.D. *has nothing to disclose.*

ODO3-10 Neuropsychology: Awareness Of Cognitive Capacities And Subjective Cognitive Decline

ODO3-10-01 Patterns of Change in Subjective Cognitive Complaints are Associated with Cognitive Decline and Dementia Risk: Findings from the Sydney Memory and Ageing Study

Katya T. Numbers, Ph.D. *has nothing to disclose.*

ODO3-10-02 Awareness of cognitive decline through the continuum of Alzheimer's disease and its association to APOE-ε4 and amyloid load

Igor Koval, Ph.D. *has nothing to disclose.*

ODO3-10-03 Pre-screening models for patient engagement, the MOPEAD Project

Mercè Boada, M.D., Ph.D. *has nothing to disclose.*

ODO3-10-04 Subjective Cognitive Decline is associated with CSF biomarkers in cognitively normal elderly individuals with a family history of AD

Steffen Wolfsgruber, Ph.D. *has nothing to disclose.*

ODO3-10-05 Comparing different approaches for operationalizing Subjective Cognitive Decline: impact on syndromic and biomarker profiles

Patricia Diaz-Galvan, Ph.D. *has nothing to disclose.*

ODO3-10-06 Reduced awareness of cognitive decline is associated to brain amyloid load in asymptomatic elderly individuals at risk for AD: a longitudinal study

Federica Cacciamani *has nothing to disclose.*

ODO3-11 Neuropsychology: Cognitive And Functional Assessment In Diverse Populations

ODO3-11-01 Montreal Cognitive Assessment-5-Minutes Protocol is Accurate in Screening for Mild Cognitive Impairment in the Rural African Population

Golden Mwakibo Masika, Ph.D. (Candidate) *has nothing to disclose.*

ODO3-11-02 The Relationships of Grip Strength and Gait Speed with Cognitive Function in a Diverse Cohort: Kaiser Healthy Aging and Diverse Life Experiences (KHANDLE) Study

Rachel A. Whitmer, Ph.D. *has nothing to disclose.*

ODO3-11-03 Latinx Brain Health Disparities in Cognitive Aging: The Role of Acculturation on Brain Integrity and Cognition Among Older HIV+ Adults

Monica Rivera Mindt, Ph.D. *has nothing to disclose.*

ODO3-11-04 Use of the NIH Toolbox for Assessment of Mild Cognitive Impairment and Alzheimer's Disease in General Population, African-American and Spanish-speaking Samples of Older Adults

Richard Gershon, Ph.D. *has nothing to disclose.*

ODO3-11-05 Subjective vs Objective Cognitive Assessment in an Ethnically Diverse Cohort of Oldest-Old Individuals: The LifeAfter90 Study

Maria M. M. Corrada, ScM, ScD *has nothing to disclose.*

ODO3-11-06 Validity of the Clinical Dementia Rating Scale sum of boxes in staging and detection of cognitive impairment in Mexican American population

Parunyou Julayanont, M.D. *has nothing to disclose.*

ODO3-12 Neuropsychology: Longitudinal Cognitive Assessment In Early Stages Of AD

ODO3-12-01 Defining Longitudinal Change on the Auditory Verbal Learning Test using a Conditional Normative Model to Account for Practice Effects: Preliminary Validation in Preclinical Alzheimer's disease

Eva Alden, Ph.D. *has nothing to disclose.*

ODO3-12-02 Accounting for Cognitive Practice Effects Results in Earlier Detection and More Accurate Diagnosis of MCI: Biomarker Confirmation

William S. Kremen, Ph.D. *has nothing to disclose.*

ODO3-12-03 Trajectory of clinical symptoms accelerates after 10 years of amyloid.

Alex C Birdsill, Ph.D. *has nothing to disclose.*

ODO3-12-04 Practice effect of repeated cognitive tests among older adults: associations with brain amyloid status and other influencing factors

Bang Zheng, M.D., MSc *has nothing to disclose.*

ODO3-12-05 Estimating an individuals' placement on a theoretical continuum using longitudinal cognitive trajectories: relationships with longitudinal amyloid and tau-PET

Michael J Properzi, BEng, BSc *has nothing to disclose.*

ODO3-12-06 Trajectories of decline in cognitively complex everyday activities across the Alzheimer's disease continuum

Mark A. Dubbelman, MSc *has nothing to disclose.*

ODO3-13 Neuropsychology: Neuropsychological Correlates Of Pathology: Novel And Standard Cognitive Markers Of Disease

ODO3-13-01 Cross-sectional differences in symptomatic presentation and cognitive performance among participants with LATE-NC compared to FTLD-TDP

Merilee Teylan, MPH *has nothing to disclose.*

ODO3-13-03 Deficits in learning are greater than memory dysfunction in preclinical Alzheimer's disease

Yen Ying Lim, Ph.D. *has nothing to disclose.*

ODO3-13-04 Comparison of Brain Atrophy and Cognitive Performance in Individuals with Low and High Cardiovascular Risk: data from the Diabetes and Dementia (D2) study

Rebecca Singleton *has nothing to disclose.*

ODO3-14 Nonhuman: Preclinical Immunotherapeutic Studies

THIS PRESENTATION IS NOT CME ACCREDITED

ODO3-14-01 Rationally designed antibodies selective for pathogenic tau aggregates

Johanne Kaplan, Ph.D. *has nothing to disclose.*

THIS PRESENTATION IS NOT CME ACCREDITED

ODO3-14-02 SYNAPTICALLY PREFERRED ANTI-TAU ANTIBODIES REDUCE IN VITRO TAU SEEDING AND IN VIVO NEURONAL LOSS

Chin-Yin Tai, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

APRINOIA Therapeutics Inc. - Salary

ODO3-14-03 Monoclonal GW-23B7 Removes A β -Pathologic Oligomers and Produces Cognitive Rescue Without Toxicity in Old TgSwDI AD Model Mice with Advanced Pathology

Fernando Goni, Ph.D. *has nothing to disclose.*

THIS PRESENTATION IS NOT CME ACCREDITED

ODO3-14-04 AAV mediated gene therapy as local treatment modality directed against amyloid beta oligomers in the brain using a high affinity, high specificity antibody

Guus Scheefhals, MSc *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

DegenRx - Ownership Interest

Crossbeta Biosciences - Ownership Interest

ODO3-14-05 Tau passive immunotherapy efficacy is modulated by antibody Fc domain

Rebecca M Nisbet, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Merck - Royalty

CME CREDIT APPROVAL PENDING

ODO3-14-06 Neuronal expression of a single-chain variable fragment antibody against A β oligomers protects synapses and rescues memory in Alzheimer models

Maria Clara Selles *has nothing to disclose.*

ODO3-15 Nonhuman: Preclinical Studies On ApoE And Neuroinflammation

ODO3-15-01 Allele specific targeting of APOEe4 expression: The novel CRISRP/Cas9- based platform for precision therapy for Alzheimer's disease

Boris Kantor, Ph.D. *has nothing to disclose.*

ODO3-15-03 Development of a platform for the discovery of new Alzheimer's Disease drugs targeting stress-induced neuroinflammation

Maria Sebastian, Ph.D. *has nothing to disclose.*

ODO3-15-04 Synbiotic-derived metabolites reduce neuroinflammatory symptoms of Alzheimer's Disease

Chad Smith, Ph.D. *has nothing to disclose.*

ODO3-15-05 Mitochondrial Translocator protein (TSPO) ligand attenuates neuroinflammation and reduces complement component C1q in a mouse model of tauopathy.

Lauren H Fairley, M.D. *has nothing to disclose.*

ODO3-15-06 A novel p75-neurotrophin receptor antagonist, EVT901, reduces neuroinflammation in the TgFAD344 rat model of Alzheimer's disease.

Alexey Kostikov, Ph.D. *has nothing to disclose.*

SFRS3-01 Neuropsychiatric Symptoms as a treatment target: recent advances by the ISTAART Neuropsychiatric Symptoms Professional Interest Area

SFRS3-01-01 Association of Tau Tangle Burden with Depressive Symptoms in Community-Dwelling Older Adults: A Longitudinal Study

Jennifer R Gatchel, M.D., Ph.D. *has nothing to disclose.*

SFRS3-01-02 White matter texture abnormalities are associated with delusional severity in a cognitively mixed sample of older adults

Corinne E. Fischer, M.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Hoffman LaRoche - Contracted Research
Vielight Inc - Contracted Research

SFRS3-01-03 Actigraphy as a proxy biomarker for motoric agitation in Alzheimer disease

Amer M. Burhan, MBChB, MSc. FRCPC *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Janssen Canada - Consulting Fees
Western University - Salary
Antheneum - Consulting Fees
SJHC London - Salary

SFRS3-01-04 The BPSD^{PLUS} Program: efficacy of a novel person-centred care approach to reduce neuropsychiatric symptoms in residents with dementia

Moyra E Mortby, Ph.D. *has nothing to disclose.*

SFTS3-01 Using Digital Technology to Drive Clinical Innovation in Brain-Behavior Relationships: A New Era in Neuropsychology

SFTS3-01-01 Introduction

Kathleen A. Welsh-Bohmer, Ph.D. *has nothing to disclose.*

SFTS3-01-02 Working Memory and Mild Cognitive Impairment: Digital Intra-Response Latency, Subcortical Nuclei, and Neuropsychological Test Performance

David J Libon, Ph.D. *has nothing to disclose.*

SFTS3-01-03 Repeated memory-based assessments- Implications for clinical trials and practice

Kathryn V. Papp, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
Digital Cognition Technologies - Consulting Fees

SFTS3-01-04 Remote Cognitive Assessment Approaches in the Dominantly Inherited Alzheimer Network (DIAN).

Jason Hassenstab, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
Takeda - Consulting Fees
Parabon Labs - Consulting Fees
Eisai - Consulting Fees

SFTS3-01-05 Global Challenges in Cognitive Assessment: How Technology will Drive Neuropsychologists to the Forefront

Rhoda Au, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
GSK - Consulting Fees
Signant Health - Consulting Fees
Evidation Health - Contracted Research
Optum Labs - Consulting Fees
Biogen - Contracted Research

SO3-02 Developing Topic Session: Developments in Clinical Trials and Cognitive Assessment

THIS PRESENTATION IS NOT CME ACCREDITED

SO3-02-01 SALVAGING COVID-19 INTERRUPTED ALZHEIMER CLINICAL TRIALS USING VIRTUAL PATIENT SIMULATIONS

Hugo Geerts, Ph.D., bachMed, PharmaMBA *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
Certara - Salary

THIS PRESENTATION IS NOT CME ACCREDITED

SO3-02-02 Efficacy and Safety of AXS-05, a Novel, Oral, NM.D.A Receptor Antagonist with Multimodal Activity, in Agitation Associated with Alzheimer's Disease: Results from ADVANCE-1, a Phase 2/3, Double-Blind, Active and Placebo-Controlled Trial

Cedric O'Gorman, M.D. *has nothing to disclose.*

THIS PRESENTATION IS NOT CME ACCREDITED

SO3-02-03 EMERGE and ENGAGE Topline Results: Phase 3 Studies of Aducanumab in Early Alzheimer's Disease

Samantha Budd Haeberlein, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Biogen - Salary

SO3-02-04 *Personalized repetitive transcranial magnetic stimulation for non-fluent and semantic variants of primary progressive aphasia*

Jordi A Matias-Guiu, Ph.D. *has nothing to disclose.*

SO3-02-05 Accuracy of automated scoring of Verbal Paired Associates in a remote data collection context

Francesca K Cormack, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Cambridge Cognition – Salary

SO3-02-06 Harmonizing the Preclinical Alzheimer Cognitive Composite for multi-cohort studies

Olivia L Hampton, BS *has nothing to disclose.*

SFRS3-02 Alzheimer's Prevention Initiative (API) Generation Program: Baseline characteristics and umibecestat results during treatment and follow-up

SFRS3-02-01 The Generation Program: Baseline characteristics of cognitively unimpaired APOE4 carriers recruited for Generation Study 1 and Generation Study 2

Pierre N. Tariot, M.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Roche - Consulting Fees

GliaCure - Consulting Fees

Chase Pharmaceuticals - Consulting Fees

Avanir - Consulting Fees

Acadia - Consulting Fees

Novartis -

Eisai - Consulting Fees

Boehringer-Ingelheim - Consulting Fees

Adamas - Ownership Interest

AbbVie - Consulting Fees

Syneos Health - Consulting Fees

Merck - Consulting Fees

Cortexyme - Consulting Fees

Axsome - Consulting Fees

ACImmune - Consulting Fees

THIS PRESENTATION IS NOT CME ACCREDITED

SFRS3-02-02 The API Generation Program: Biomarker phenotyping of cognitively unimpaired participants screened in Generation Study 1 and Generation Study 2

Marie-Laure Rouzade-Dominguez, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
Novartis Pharma AG - Salary, Ownership Interest

THIS PRESENTATION IS NOT CME ACCREDITED

SFRS3-02-03 Umibecestat in the API Generation Program: Worsening in RBANS and/or CDR on treatment reverses after wash-out

Ana Graf, M.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

SFRS3-02-04 The API Generation Program: Umibecestat treatment and discontinuation effects on hippocampal and whole brain volumes in the overall population and amyloid-negative APOE4 homozygotes

Eric M. Reiman, M.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Denali - Consulting Fees
Alkahest - Consulting Fees
United Neuroscience - Consulting Fees
MagQ - Consulting Fees
Aural Analytics - Consulting Fees
Takeda/Zinfandel - Consulting Fees
Green Valley - Consulting Fees
Alzheon - Consulting Fees
Roche/Roche Diagnostics -

SO3-01 Neuropsychiatry and Behavioral Neurology: DLB And FTD - Clinical Manifestations

SO3-01-01 Identification of subtypes for the behavioral variant of frontotemporal dementia based on the assessment of disinhibition and compulsion

Valérie Godefroy, Ph.D. *has nothing to disclose.*

SO3-01-02 Evolution of the Core Clinical Features of Dementia with Lewy Bodies

Parichita Choudhury, M.D., MS *has nothing to disclose.*

SO3-01-03 Dementia with Lewy Bodies: Characteristics of the Prodromal Stage in a Nationwide Longitudinal Cohort

Frédéric Blanc, M.D., Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Biogen -

SO3-01-04 Studying the Natural History of Frontotemporal Lobar Degeneration (FTLD): The ARTFL LEFFTDS Longitudinal FTLD (ALLFTD) Protocol

Bradley F. Boeve, M.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Tau Consortium - Consulting Fees

Alector - Contracted Research

EIP Pharma - Contracted Research

SO3-01-05 Prevalence of FTD Clinical Diagnostic Features in patients with TDP-43 Pathology

Atri Chatterjee, DM *has nothing to disclose.*

SO3-01-06 Mild cognitive impairment with Lewy Bodies: Clinical characteristics and risk factors for progression

Marleen van de Beek, MSc. *has nothing to disclose.*

SSYM3-01 Using Technology to Improve Access To Cognitive Assessments And Interventions

SSYM3-01-01 Unsupervised Online Neuropsychological Testing – The Principles

Paul T Maruff, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Cogstate - Salary

SSYM3-01-03 Socially Assistive Robots for Cognitive and Social Stimulation

Jesus Favela, Ph.D. *has nothing to disclose.*

THIS PRESENTATION IS NOT CME ACCREDITED

SSYM3-01-04 Testing on Mobile Devices

Simon L Collinson, DPhil *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Savonix - Ownership Interest

SFRS3-03 Methodologic development and advancements in clinical trials targeting vascular cognitive impairment and dementia (VCID)

SFRS3-03-01 Developing appropriate methodologies for effective clinical trial engagement in vascular cognitive impairment and dementia (VCID)

Lon Schneider, M.D., MS *has nothing to disclose.*

SFRS3-03-02 Science and Biomarkers of Vascular Contributions to Cognitive Impairment and Dementia (VCID)

Alzheimer's Association International Conference® 2020

Roderick A Corriveau, Ph.D. *has nothing to disclose.*

SFRS3-03-03 EPIDEMIOLOGY INFORMS RANDOMIZED CLINICAL TRIALS OF COGNITIVE IMPAIRMENTS AND LATE-ONSET, SPORADIC DEMENTIAS

Deborah R Gustafson, MS, Ph.D. *has nothing to disclose.*

SFRS3-03-04 Subject selection and identification of optimal clinical outcome measures in dementia trials focused on vascular cognitive impairment and dementia

Ruth Peters, Ph.D. *has nothing to disclose.*

SFRS3-04 The transitional stage 2 of Alzheimer's disease – clinical features, biomarkers and longitudinal course

SFRS3-04-01 The dynamic interplay between longitudinal subjective and objective cognitive decline along the early AD spectrum in the Harvard Aging Brain Study

Rebecca Amariglio, Ph.D. *has nothing to disclose.*

SFRS3-04-02 NIA-AA AD Framework Stage 2: Performance in the Community

Ronald C. Petersen, M.D., Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Genentech, Inc. - Consulting Fees

Biogen, Inc. - Consulting Fees

Roche, Inc. - Consulting Fees

GE Healthcare - Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agent

Merck, Inc. - Consulting Fees

Eisai, Inc. - Consulting Fees

SFRS3-04-03 Determinants of cognitive decline and dementia in stage 2: the SCIENCE project

Wiesje van Der Flier *has nothing to disclose.*

SFRS3-04-04 Cognitive and biological characteristics of stage 2 of AD in the clinical multicenter DELCODE study

Frank Jessen, M.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Esai - Consulting Fees

Janssen Cilag - Consulting Fees

Biogen - Consulting Fees

GE Healthcare - Consulting Fees

AC immune - Consulting Fees

Roche - Consulting Fees

SSYM3-02 Repurposing Drugs Targeting Glia and Inflammatory Mechanisms

CME CREDIT APPROVAL PENDING

SSYM3-02-01 Targeting s0ITNF to Reduce Risk and Progression of Alzheimer's Disease And Other Dementias

Malu Gamez Tansey, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

INmune Bio - Consulting Fees

Xencor Inc. - Receipt of Intellectual Property Rights/Patent Holder

CME CREDIT APPROVAL PENDING

SSYM3-02-02 Repurposing Senolytic Therapies For Alzheimer's Disease

Howard M Fillit, M.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Otsuka - Consulting Fees
Genentech - Consulting Fees
Merck - Consulting Fees
Axovant - Consulting Fees
vTv Therapeutics - Consulting Fees
Lundbeck - Consulting Fees

THIS PRESENTATION IS NOT CME ACCREDITED

SSYM3-02-03 Microglial Cells In AD: Good Guys Or Bad Guys?

Knut Biber, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

AbbVie Deutschland GmbH & Co. KG - Salary

CME CREDIT APPROVAL PENDING

SSYM3-02-04 Finding New Uses For Old Drugs In Alzheimer's Disease

Clive Ballard, MBChB *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Synexus - Consulting Fees, Contracted Research
NSC Therapeutics - Consulting Fees
Lundbeck - Consulting Fees
Acadia - Consulting Fees
Roche - Consulting Fees
Novo Nordisk - Contracted Research, Consulting Fees
GE Healthcare -
AARP - Consulting Fees
Oryzon - Contracted Research
Novartis - Contracted Research
Excivia - Consulting Fees

SFRS3-05 Biomarkers and Early Diagnosis of DLB: New Findings.

SFRS3-05-01 The Complexity of DLB: US Based Dementia with Lewy Body Consortium

James B Leverenz, M.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Sanofi - Contracted Research
Eisai -
Acadia - Consulting Fees
GE Healthcare - Consulting Fees

SFRS3-05-02 Neuroimaging biomarkers in prodromal DLB

Kejal Kantarci, M.D., MS *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Takeda - Consulting Fees

Avid Radiopharmaceuticals - Contracted Research

SFRS3-05-03 EEG biomarkers for the early diagnosis of DLB

Laura Bonanni, M.D., Ph.D. *has nothing to disclose.*

SFRS3-05-04 CSF and plasma biomarkers for DLB

Doug R. Galasko, M.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

vTv Therapeutics - Consulting Fees

Fujirebio, Inc - Consulting Fees

Cognition Therapeutics - Consulting Fees

THIS PRESENTATION IS NOT CME ACCREDITED

SFTS3-02 Results of the DIAN-TU Prevention Trial of Solanezumab and Gantenerumab in Dominantly Inherited Alzheimer's Diseaseon-demand presentations accompany this session and are recommended viewing in advance**

SFTS3-02-01 Panel Discussion: DIAN-TU Trial Collaborative Effort (NOTE: NO PRE-RECORDING NEEDED BY PANELISTS)

Randall J Bateman, M.D., Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Janssen - Contracted Research

DIAN-TU Pharma Consortium -

Hoffman La-Roche/Genentech - Contracted Research, Consulting Fees

C2N Diagnostics - Ownership Interest

Tau Silk Consortium -

Eli Lilly & Co - Contracted Research

Avid Radiopharmaceuticals - Contracted Research

Maria C. Carrillo, Ph.D. *has nothing to disclose.*

Martin R. Farlow, M.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Novartis - Contracted Research

Longeveron - Consulting Fees

Eli Lilly - Contracted Research, Consulting Fees

Danone - Consulting Fees

Chemigen - Consulting Fees

AZTherapies - Consulting Fees

Allergan - Consulting Fees

Takeda - Consulting Fees

Proclara (formerly Neurophage Pharmaceuticals) - Consulting Fees

Neurotrope Biosciences - Consulting Fees

Green Valley - Consulting Fees

Elan, Transgenic Mouse Model Patent licensed to Elan - Royalty

Cortexyme - Consulting Fees

Cerecin (formerly Accera) - Consulting Fees

Avanir - Consulting Fees

ADCS Posiphen - Contracted Research

Zhejiang Hisun Pharmaceuticals - Consulting Fees

Suven Life Sciences - Contracted Research

Otsuka - Consulting Fees

Medavante - Consulting Fees

Genentech - Contracted Research

Eisai - Consulting Fees, Contracted Research

Cognition Therapeutics - Consulting Fees

Biogen - Contracted Research, Consulting Fees

AstraZeneca - Contracted Research

AbbVie - Contracted Research

vTv Therapeutics - Consulting Fees, Contracted Research

Samumed - Consulting Fees

Geoffrey A Kerchner, M.D., Ph.D. *has nothing to disclose.*

Laurie M Ryan, Ph.D. *has nothing to disclose.*

Stephen P. Salloway, M.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eli Lilly & Co - Contracted Research, Consulting Fees

Avid - Contracted Research, Consulting Fees

Roche/Genentech - Consulting Fees, Contracted Research

Eisai - Contracted Research, Consulting Fees

Novartis - Contracted Research, Consulting Fees

Biogen - Consulting Fees, Contracted Research

Roy Yaari, M.D. *has nothing to disclose.*

Thursday, July 30, 2020, AAIC Disclosures

12:00 a.m. — 11:59 p.m. Central Daylight Time (North America)

ODFRS4-01 Advancing Clinical Trial Design and Methods in a Digital Age

ODFRS4-01-01 Introduction

Howard H. Feldman, M.D. *has nothing to disclose.*

ODFRS4-01-02 Computerized Neuropsychological Tests undertaken on digital platforms are cost effective, achieve high engagement, distinguish and are highly sensitive to longitudinal change: Data from the PROTECT and GBIT studies

Adam Hampshire, Ph.D. *has nothing to disclose.*

ODFRS4-01-03 Intensive Measurement of Cognition to Support Early Detection of Cognitive Change in Individuals at Risk of Dementia

Paul Brewster, Ph.D. *has nothing to disclose.*

ODFRS4-01-04 Relationship between genetic risk for Alzheimer's, cognition and neuropsychiatric symptoms: a case study of DNA sampling and analysis through digital platform cohort studies.

Byron Creese, Ph.D. *has nothing to disclose.*

ODFRS4-01-05 The *Brain Health Support Program*: A web-based interactive platform to increase dementia literacy and awareness regarding lifestyle factors in at-risk individuals.

Sylvie Belleville, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
Sojerci - Consulting Fees

ODFRS4-02 Development and validation of cognitive and quality of life assessments for older Indigenous peoples internationally

ODFRS4-02-01 The validity of the Good Spirit, Good Life quality of life tool for older Aboriginal Australians

Kate Smith, Ph.D. *has nothing to disclose.*

ODFRS4-02-02 The validation of the adapted Kimberley Indigenous Cognitive Assessment in a Brazilian indigenous community of older adults from Amazonas

Juliana Nery Souza-Talarico, Ph.D. *has nothing to disclose.*

ODFRS4-02-03 Māori Assessment of Neuropsychological Abilities (MANA), a cognitive, functional and wellbeing screening tool for dementia in older Māori

Makarena Diana Dudley, Ph.D., PGDipClinPsych *has nothing to disclose.*

ODFRS4-02-04 Adaptation of the Canadian Indigenous Cognitive Assessment in three provinces and evidence for validity

Jennifer D Walker, Ph.D. *has nothing to disclose.*

ODFRS4-03 Hearing Impairment and the Aging Brain: Mechanisms, Practical Considerations and the Effect of Treatment in Older Adults

ODFRS4-03-01 Hearing loss and microstructural integrity of the brain in a dementia-free older population

Pauline H Croll, MSc *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
Cochlear Ltd - Salary

ODFRS4-03-02 Functional hearing loss as a marker for early Alzheimer's disease and dementia: exploring the potential for reverse causation

Willa D Brenowitz, Ph.D., MPH *has nothing to disclose.*

ODFRS4-03-03 Hearing loss and cognition: A protocol for ensuring speech understanding in neuropsychological assessment

Adele M Goman, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
Auditory Insight - Consulting Fees

ODFRS4-03-04 The Aging and Cognitive Health Evaluation in Elders (ACHIEVE) trial: Recruitment and baseline data of a randomized trial of hearing treatment for reducing cognitive decline

Nicholas S Reed, AuD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
Helen of Troy - Consulting Fees

ODFRS4-05 Intersections of sex/Gender and race/ethnicity in cognitive aging and Alzheimer's disease trajectories

ODFRS4-05-01 Trends in sex/gender differences across Whites, Blacks, and Hispanics

Justina F Avila, M.A. *has nothing to disclose.*

ODFRS4-05-02 Sex differences in neurodegeneration and memory performance in preclinical autosomal dominant Alzheimer's disease: Baseline findings from the API ADAD Trial

Clara Vila-Castelar, Ph.D. *has nothing to disclose.*

ODFRS4-05-03 Socioeconomic status mediating sex and racial differences using the AT(N) framework

Karin L. Meeker, Ph.D. *has nothing to disclose.*

ODFRS4-05-04 Gender and sex bias in clinical trials recruitment in Alzheimer's disease: Findings from Fundació ACE

Carla Abdelnour, M.D. *has nothing to disclose.*

ODFRS4-06 Latino cognitive aging: from genes to daily function

ODFRS4-06-01 APOE alleles association with neurocognitive function differ across Hispanic background groups

Einat Granot-HersHKovitz, Ph.D. *has nothing to disclose.*

ODFRS4-06-02 Cardiovascular and stroke risk, cognitive change, and Mild Cognitive Impairment: Results from the HCHS/SOL and SOL-INCA

Wassim Tarraf, Ph.D. *has nothing to disclose.*

ODFRS4-06-03 Subjective Cognitive Decline is associated with neurocognition in the SOL-INCA study

Zvinka Zlatar, Ph.D. *has nothing to disclose.*

ODFRS4-06-04 Daily functioning and cognition: Results from the Hispanic Community Health Study/Study of Latinos (SOL) and Study of Latinos - Investigation of Neurocognitive Aging (SOL-INCA)

Ariana Stickel, Ph.D. *has nothing to disclose.*

ODFRS4-07 New insights in determinants of dementia to advance prevention strategies: a view from Latin America and African countries

ODFRS4-07-01 Socioeconomic determinants of dementia in Caribbean Hispanics: An International Comparison

Jorge J Llibre-Guerra, M.D., MSc *has nothing to disclose.*

ODFRS4-07-02 Risk factors for dementia in Cuban older adults

Geeske Peeters, Ph.D. *has nothing to disclose.*

ODFRS4-07-03 Multimorbidity as a correlate of dementia among older people in Central Africa: the EPIDEMCA study

Maëlénn M Guerchet, Ph.D. *has nothing to disclose.*

ODFRS4-07-04 Cognitive dysfunction is common in middle-aged adults with type 2 diabetes in South Africa

Kirsten Bobrow, MBChB, DPhil *has nothing to disclose.*

ODFRS4-08 Novel insights into the role of vascular risk factors in the development of Alzheimer's disease and neurodegeneration

Alzheimer's Association International Conference® 2020

ODFRS4-08-01 Brain atrophy coupled to cognitive decline 3 years after stroke

Amy Brodtmann, MBBS, Ph.D. *has nothing to disclose.*

ODFRS4-08-02 Vascular Risk and Physical Activity as Modulators of Cognitive and Neurodegenerative Trajectories: Independent and Interactive Effects with Beta-Amyloid

Jasmeer P. Chhatwal, M.D., Ph.D., MSc *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Otsuka Pharmaceuticals - Consulting Fees

ODFRS4-08-03 Cognitive and imaging impacts of left ventricular hypertrophy in people with Type 2 Diabetes

Carolina Restrepo, Ph.D. *has nothing to disclose.*

ODFRS4-08-04 Capturing longitudinal impacts on cognition following stroke in rodent models using touchscreen testing

Jess Nithianantharajah, Ph.D. *has nothing to disclose.*

ODFRS4-09 Nutrition, the unrecognized determinant of Alzheimer's disease

ODFRS4-09-01 The impact of a nutritional intervention in prodromal Alzheimer's disease: The LipiDiDiet clinical trial

Tobias Hartmann, Ph.D. *has nothing to disclose.*

ODFRS4-09-02 Brain tocopherol levels are associated with lower activated microglia density in elderly human cortex

Francisca A. de Leeuw, M.D. *has nothing to disclose.*

ODFRS4-09-03 Associations of nutritional parameters with clinical progression in patients with subjective cognitive decline, mild cognitive impairment and Alzheimer's disease: the NUDAD project

Astrid S Doorduijn, MSc *has nothing to disclose.*

ODFRS4-09-04 Gene-diet interaction and dementia risk: the example of coffee and CYP1A2 gene

Sophie Lefèvre-Arbogast, Ph.D. *has nothing to disclose.*

ODFRS4-10 Reserve & Resilience: Opportunities and Mechanisms for Dementia Prevention

ODFRS4-10-01 Global system segregation enhances reserve in normal aging and Alzheimer's disease

Julia Neitzel, Ph.D. *has nothing to disclose.*

ODFRS4-10-02 Cognitive reserve and resilience- possible mechanisms of dementia prevention

Gill Livingston, MBChB, M.D. *has nothing to disclose.*

ODFRS4-10-03 SuperAging: A model for studying mechanisms of resilience and resistance

Emily J Rogalski, Ph.D. *has nothing to disclose.*

ODFRS4-10-04 Doing More with Less: Women's Higher Brain Metabolic Rate Compensates for Early Alzheimer's Pathological Changes

Erin E Sundermann, Ph.D. *has nothing to disclose.*

ODFRS4-11 What can longitudinal cohorts tell us about the association between modifiable dementia risk factors and the ageing brain?

ODFRS4-11-01 Longitudinal aortic stiffness is associated with brain microstructure and cognition: A voxel-wise magnetic resonance imaging study

Sana Suri, MSc (Oxon.), DPhil (Oxon.) *has nothing to disclose.*

ODFRS4-11-02 Association of trajectories of depressive symptoms with vascular risk factors, cognitive function and adverse brain outcomes: a 28-year follow-up

Naiara Demnitz, MSc, DPhil *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
Alzheimer's Association -

ODFRS4-11-03 Trajectory of apathy, cognition and neural correlates in the decades before symptoms in frontotemporal dementia

Timothy Rittman, BMBS, BMedSci, MRCP, Ph.D. *has nothing to disclose.*

ODFRS4-11-04 Validation of composite proxy measures of cognitive reserve

Rory Boyle, MSc *has nothing to disclose.*

ODO4-01 Dementia Care and Psychosocial Factors: Dementia - Cross-Cultural Investigations

ODO4-01-01 A systematic review of culturally tailored dementia interventions for minority ethnic groups and low- and middle-income country populations: acceptability, feasibility and outcomes.

Tiffeny James, MSc *has nothing to disclose.*

ODO4-01-02 Informal care time in dementia by cognitive, functional and behavioral disease severity from 8 longitudinal cohorts across multiple countries.

Ron Handels, Ph.D. *has nothing to disclose.*

ODO4-01-03 Improving the experience of dementia and enhancing active life (IDEAL): investigating the perspectives of people from ethnic minority communities

Eleanor van den Heuvel, MSc *has nothing to disclose.*

ODO4-01-04 Attitudes towards people with dementia: Questionnaire validation and comparison between Germany and China

Johannes Pantel, M.D., Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Schwabe - Consulting Fees

Infectopharm - Consulting Fees

Merck KGaA - Salary

ODO4-01-05 Cross-cultural acceptability of interventions at the end of life in dementia: video vignette study design and pilot evaluation (ERC CONT-END WP1)

Jenny T. van der Steen *has nothing to disclose.*

ODO4-01-06 Spanish translation and cultural adaptation of the Memory Support System: A pilot study

Octavio A Santos, Ph.D. *has nothing to disclose.*

ODO4-02 Dementia Care and Psychosocial Factors: Long-Term Care And Ethics

ODO4-02-01 People living alone with dementia: Ethical guidelines for social research

Kate de Medeiros, Ph.D. *has nothing to disclose.*

ODO4-02-02 Optimizing Practices, Use, Care and Services-Antipsychotics(OPUS-AP): a phase 2 scale-up to 129 Long-term Care (LTC) centers in Quebec, Canada

Benoit Cossette, BPharm, Ph.D. *has nothing to disclose.*

ODO4-02-03 To Be Alive vs. To Live: Filipino Elderly, Nasogastric Tubes, and the Issue of Artificial Feeding in Dementia

Carla Krishan A. Cuadro, Ph.D. Cand. *has nothing to disclose.*

ODO4-03 Dementia Care Practice: Improving Dementia Care Within Health Systems

ODO4-03-01 Development of a digital system to assess and manage unmet needs of family dementia caregivers in clinical practice

Olga A. Klein, Ph.D. *has nothing to disclose.*

ODO4-03-02 Everyday life priorities and health care preferences of patients living with dementia or cognitive impairment – a systematic review

Hannah Wehrmann *has nothing to disclose.*

ODO4-03-03 Integrated Memory Care Clinic: Primary Care for People Living with Dementia

Carolyn K Clevenger, DNP *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
Acadia Pharmaceuticals - Consulting Fees

ODO4-03-04 Integrating Primary/Secondary Medical Care with Community Social Care: Findings from a Formative Evaluation Study of a Hong Kong Government Pilot Scheme

Gloria HY Wong, Ph.D. *has nothing to disclose.*

ODO4-03-05 Agents of Change: Establishment of quality improvement collaboratives to improve the quality of dementia care in Australia

Kate Laver, Ph.D. BOccThy *has nothing to disclose.*

ODO4-03-06 Capacity of the health facilities to manage Alzheimer's and related dementia diseases in Mukono district: Challenges and recommendations.

Stephen Samuel Joloba, MPH *has nothing to disclose.*

ODO4-04 Dementia Care Practice: Supporting Communities To Deliver Quality Dementia Care

ODO4-04-01 Stakeholder Engagement for Successful Practice Change in Long-term Care: Evaluating the Feasible and Sustainable Culture Change Initiative (FASCCI) Model

Sienna Caspar, Ph.D. *has nothing to disclose.*

ODO4-04-02 A Dementia-Friendly Faith Village Community Program to Support African American Families

Fayron Epps, Ph.D., RN *has nothing to disclose.*

ODO4-04-03 Community-based participatory approach to promote convenience stores' support for older adults with dementia in Japan

Ayumi Igarashi, Ph.D., RN *has nothing to disclose.*

ODO4-04-04 iSupport-Portugal: Adapting an evidence-based online intervention for dementia caregivers to a different culture

Soraia Teles, M.S. *has nothing to disclose.*

ODO4-04-05 Caregiver-Centered Care Health Workforce Competencies: Taking Steps to Support Family Caregivers of People living with Dementia throughout the Care Trajectory.

Jasneet Parmar, MBBS, MCFP(COE), MSc. *has nothing to disclose.*

ODO4-04-06 Dementia Care Practice: Integrating Medical and Caregiver Support in a Community-Based Program

Virginia H. Templeton, M.D. *has nothing to disclose.*

ODO4-05 Dementia Care Research: Dementia Care - Caregiving

ODO4-05-01 Family Availability and Its Influence on Informal and Formal Care Used by Adults with Dementia in the United States

HwaJung Choi, Ph.D. *has nothing to disclose.*

ODO4-05-02 Caregiving is associated with worse sleep, and worse sleep-related health and function.

Kate E Sprecher, Ph.D. *has nothing to disclose.*

ODO4-05-03 Intermediate Outcomes of a Randomized Trial of Tele-Savvy, an Online Psychoeducation Program

Kenneth Hepburn *has nothing to disclose.*

ODO4-05-04 Effects of Bibliotherapy on Improving Caregiving Appraisal and Coping among Informal Caregivers of People with Dementia: a Pilot Randomized Controlled Trial

Shanshan Wang, Ph.D. candidate *has nothing to disclose.*

ODO4-05-05 Internet-based supportive interventions for family caregivers of people with dementia: A systematic review and meta-analysis

Minmin Leng, M.D. *has nothing to disclose.*

ODO4-05-06 The State of the Science on Synchronous Video-Conferencing Interventions for Care Partners of Persons with Dementia

Robin R Tarter, RN, MSN, Ph.D. Student *has nothing to disclose.*

ODO4-06 Dementia Care Research: Dementia Care - Evaluation

ODO4-06-01 Development of international practice recommendations for the recognition and management of hearing, vision and cognitive impairment

Jenna Louise Littlejohn, BSc MSc Ph.D. *has nothing to disclose.*

ODO4-06-02 Assessing the Reliability of Reported Medical History in Older Adults

Gregory S Day, M.D., MSc *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
Parabon Nanolabs Inc - Ownership Interest, Consulting Fees
DynaMed - Consulting Fees

ODO4-06-03 What older adults do with results from a community-based dementia screening program.

James E Galvin, M.D., MPH *has nothing to disclose.*

ODO4-06-04 Evaluating Everyday Preferences Assessment Over Time Between People with Cognitive Impairment and their Care Partners

James M Wilkins, M.D., DPhil *has nothing to disclose.*

ODO4-06-05 Use of wearable technology to assess activity in cognitively impaired populations: inside care homes and the community

Riona Mc Ardle, Ph.D. *has nothing to disclose.*

ODO4-06-06 Investigating the feasibility of using wearable technologies and machine learning techniques to recognise distress and agitation in people living with dementia

Zeke Steer, MEng *has nothing to disclose.*

ODO4-07 Dementia Care Research: Dementia Care - Models Of Care

ODO4-07-01 Policy, Practice and Public Awareness: A review of national and international approaches to improve diagnosis and post-diagnostic support for people living with dementia.

Marie Poole, Ph.D., MSc Health Sciences, BA Sociology *has nothing to disclose.*

ODO4-07-02 *Benefits of home-based dementia care on clinical and quality of life outcomes for persons living with dementia and their carers*

Quincy M Samus, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Centene Corp -

ODO4-07-03 A Novel Care Model for Dementia: Improving Caregiver Burden and Depression

Carol A Manning, Ph.D., ABPP-CN *has nothing to disclose.*

ODO4-07-04 Supporting Caregivers to Increase Confidence Can Delay Functional Decline in Older Adults

Machiko R Tomita, Ph.D. *has nothing to disclose.*

ODO4-07-05 The effect of educational intervention by tele-nursing on caregiver burden in family caregivers of elderly with Alzheimer's disease

leila sadeghmoghadam, PhD *has nothing to disclose.*

ODO4-07-06 The sustainability of community interventions for people affected by dementia: A realist review

Thomas Alexander Morton, MA, MSc *has nothing to disclose.*

ODO4-08 Epidemiology: Cardiovascular Risk Factors

ODO4-08-01 Examining the causal mediating role of cardiovascular disease on the relationship between subclinical cardiovascular disease and cognitive impairment: The Cardiovascular Health Study

Ryan M Andrews, Ph.D. *has nothing to disclose.*

ODO4-08-02 Decreased complexity and increased variability in systolic blood pressure are associated with elevated long-term risk of dementia: The Rotterdam Study

Yuan Ma, M.D., Ph.D. *has nothing to disclose.*

ODO4-08-03 Visit-to-visit Blood Pressure Variability Is Associated With Functional Decline In Older Adults: the S.AGES Cohort

Laure Rouch, PharmD, Ph.D. *has nothing to disclose.*

ODO4-08-04 Weight loss predicts Alzheimer's disease biomarker positivity in cognitively unimpaired middle-aged adults

Oriol Grau-Rivera, M.D., Ph.D. *has nothing to disclose.*

ODO4-08-05 Reported chronic high glycemic diet intake predicts amyloid deposition in the precuneus of cognitively normal older adults over one-year.

Matthew K Taylor, Ph.D. *has nothing to disclose.*

ODO4-08-06 Antihypertensive medication classes and the risk of dementia: a systematic review and network meta-analysis

Melina G.H.E. den Brok, M.D. *has nothing to disclose.*

ODO4-09 Epidemiology: Early Life Exposures In Diverse Cohorts

ODO4-09-01 Relationship between state-level administrative school quality data, years of education, cognitive decline, and dementia risk

Jennifer J Manly, Ph.D. *has nothing to disclose.*

ODO4-09-02 Racial/Ethnic differences in the association of high school quality with later life cognitive function

Dominika Seblova, Ph.D. *has nothing to disclose.*

ODO4-09-03 Gender differences in the association of childhood socioeconomic status and late-life cognition among African Americans: Findings from the STAR Study

Paola Gilsanz, ScD *has nothing to disclose.*

ODO4-09-04 Cardiovascular Risk Factors in Adolescence and Adulthood and Late-Life Cognition: Study of Healthy Aging in African Americans (STAR)

Rachel Peterson, Ph.D., MPH, MA *has nothing to disclose.*

ODO4-09-05 Lifetime stressful experiences and cognitive performance in African American and White older adults: New evidence from a population-based cohort.

Megan Zuelsdorff, Ph.D. *has nothing to disclose.*

ODO4-09-06 Holocaust survivorship and late-life cognitive performance in Men with Coronary Heart Disease

David Tanne, M.D. *has nothing to disclose.*

ODO4-10 Epidemiology: Effects Of Air Pollution On Cognition

ODO4-10-01 Long-term exposure to ambient air pollution and risk of dementia: results of the prospective Three-City study

Marion Mortamais, Ph.D. *has nothing to disclose.*

ODO4-10-02 The association between ambient air pollution and cognitive impairment in community-dwelling older adults: 6-year Cohort Study TIGER

Yen-Ching Chen, ScD *has nothing to disclose.*

ODO4-10-03 Lower levels of episodic memory associated with long-term air pollution exposures in older women: differences in midlife versus late-life exposures and effect modification by hormone treatment

Xinhui Wang, Ph.D. *has nothing to disclose.*

ODO4-10-04 Heterogeneous air pollutant exposure effects on episodic memory decline: evidence from WHIMS-ECHO study

Andrew J. Petkus, Ph.D. *has nothing to disclose.*

ODO4-10-05 Air pollution and biomarkers of Alzheimer's disease in cognitively unimpaired individuals

Marta Crous-Bou, Ph.D. *has nothing to disclose.*

ODO4-10-06 Increased Neuroanatomic Risk for Alzheimer's Disease at Preclinical Stage: Exploring the Interaction of Fine Particle Exposure and Psychosocial Stress

Diana Younan, Ph.D., MPH *has nothing to disclose.*

ODO4-11 Epidemiology: Lifestyle Risk Factors

ODO4-11-01 Participation in leisure activities and risk of dementia: results from Whitehall II study with 18-year follow-up

Andrew Sommerlad, MRCPsych, Ph.D. *has nothing to disclose.*

ODO4-11-03 Trajectory of physical activity and risk of dementia: a national-based cohort study

Natan Feter, MS *has nothing to disclose.*

ODO4-11-04 Healthy dietary patterns are associated with better cognitive performance in older adults: findings from National Health and Nutrition Examination Survey (NHANES) 2011-2014

Yian Gu, Ph.D. *has nothing to disclose.*

ODO4-11-05 Pathways involved in the relationship between resilience and cognitive function: The Memento cohort

Leslie Grasset, Ph.D. *has nothing to disclose.*

ODO4-11-06 Lifestyle and genetic risk: Revisiting the association with incident dementia

Jessica D Faul, Ph.D., MPH *has nothing to disclose.*

ODO4-12 Epidemiology: Sensory Impairment And Cognition

ODO4-12-01 What am I measuring? Disentangling cognitive status from sensory impairment

Emma Nichols, MPH *has nothing to disclose.*

ODO4-12-02 Hearing aid use and cognition in older adults: Can we delay decline or even improve cognitive function?

Julia Sarant, Ph.D. *has nothing to disclose.*

ODO4-12-03 Visual impairment and dementia risk in two population-based prospective cohorts

Thomas J Littlejohns, Ph.D. *has nothing to disclose.*

ODO4-12-04 Relationship of hearing impairment with MRI brain volumes and cognitive decline in the Atherosclerosis Risk in Communities Study

Jennifer A Deal, Ph.D. *has nothing to disclose.*

ODO4-12-05 Cataract surgery is associated with reduced risk for Alzheimer's disease

Cecilia S Lee, M.D., MS *has nothing to disclose.*

ODO4-12-06 Hearing loss and Hearing Care Disparities among Older Adults with Cognitive Impairment

Carrie L Nieman, M.D., MPH *has nothing to disclose.*

ODO4-13 Health Services Research: Cost Of Care And Implications For Intervention

ODO4-13-01 Alzheimer's and Related Dementia (ADRD) Episode Payments and 30-day Readmission Rate and Timing Comparing Skilled Nursing Facility and Home Health Discharge Destinations in a Statewide Collaborative

Neil Kamdar, MA *has nothing to disclose.*

ODO4-13-02 Hospitalization Expenses Attributable to Cognitive-frailty elderly in China

ying yang *has nothing to disclose.*

ODO4-13-03 Linking electronic dementia care records to national inpatient data in Dementia with Lewy bodies: Frequency, duration and cost implications of hospitalization and recording of delirium episodes

Christoph Mueller, M.D. *has nothing to disclose.*

ODO4-13-04 Dementia Diagnosis Disparities by Race and Ethnicity

Pei-Jung Lin, Ph.D. *has nothing to disclose.*

ODO4-13-05 Effective interventions for potentially modifiable dementia risk factors: their costs and cost-effectiveness

Naaheed Mukadam, BMBCh, MRCPsych, MA, MSc, Ph.D. *has nothing to disclose.*

ODO4-14 Prevention (non-pharmacological): Developing ADRD Non-pharmacological Intervention Targets

ODO4-14-01 Dietary Patterns and Cognitive decline among Older Adults: Findings from Sydney Memory and Aging Study

Xi Sophie Chen, Master of nutrition and dietetics *has nothing to disclose.*

ODO4-14-02 Dietary Intake of the Bioactive Pelargonidin May Slow Decline in Multiple Cognitive Abilities

Thomas Monroe Holland, M.D. *has nothing to disclose.*

ODO4-14-03 Methylation status and sulfur amino-acids as risk factors for cognitive decline over 15 years: A longitudinal population based study

Babak Hooshmand, M.D., Ph.D., MPH *has nothing to disclose.*

ODO4-14-04 Standing activity as assessed by seismic accelerometers and cognitive function in community-dwelling older adults: The MIND trial

Shannon Halloway, Ph.D., RN *has nothing to disclose.*

ODO4-14-05 Sitting Time, Physical Activity, and Cognitive Impairment in Mid-Life Adults: Findings from the Cooper Center Longitudinal Study

Galit Weinstein, Ph.D. *has nothing to disclose.*

ODO4-14-06 Cumulative effects of sleep quality on risk for incident mild cognitive impairment (MCI): Results from the Einstein Aging Study Cohort (EAS)

Carol A. Derby, Ph.D. *has nothing to disclose.*

ODO4-15 Prevention: ADRD Prevention Research: Who Is At Risk And Who Benefits More?

ODO4-15-01 Socioeconomic inequalities in cognitive function in midlife and early late life partially attributable to modifiable health and lifestyle factors

Susanne Roehr, Ph.D. *has nothing to disclose.*

ODO4-15-02 Long-term dietary intervention adherence among individuals with elevated risk of dementia: the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER).

Jenni Lehtisalo, Ph.D. *has nothing to disclose.*

ODO4-15-03 Effect of multidomain interventions on estimated dementia and cardiovascular risk reduction: an individual-participant data meta-analysis from FINGER, MAPT, and Pre-DIVA.

Mariagnese Barbera, Ph.D. *has nothing to disclose.*

ODO4-15-04 Examining Risk of Dementia in Lifestyle Engagement Subgroups of Community-Dwelling Older Adults: A Latent Class Approach

Kyle D. Moored, BS *has nothing to disclose.*

ODO4-15-05 APOE4, Lifestyle Factors, and Cognitive Decline; a Population-Based Cohort Study

Klodian Dhana, M.D., Ph.D. *has nothing to disclose.*

ODO4-16 Psychosocial Factors and Environmental Design: Technology and Interventions

ODO4-16-01 Building Consensus in Dementia Policy Goals: A Delphi Study in Hong Kong

Gloria HY Wong, Ph.D. *has nothing to disclose.*

ODO4-16-02 Understanding caregiver profiles of older adults reporting cognitive decline – a descriptive study from North India

Jayashree Dasgupta, Ph.D. *has nothing to disclose.*

ODO4-16-03 Measuring Dose in a Tailored Lighting Intervention to Improve Sleep and Mood in Alzheimer's Disease Patients

Mariana G Figueiro, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

USAI Lighting - Contracted Research
Ketra - Contracted Research
CREE - Contracted Research
OSRAM - Contracted Research
Erik Page Associates - Contracted Research
Axis Lighting - Contracted Research
View Glass - Contracted Research
LEDvance - Contracted Research
Current Powered by GE - Contracted Research
Armstrong Ceiling and Walls - Contracted Research

ODO4-16-04 Creating technology for and with people with MCI and dementia in the workplace

Karan Shastri, MEng *has nothing to disclose.*

ODO4-16-05 Assessment of Emerging Mobile Connected Technologies to Promote Outdoor Mobility and Transit in Older Adults and in those with Alzheimer's Disease and Related Dementias: Usability, Stressors, Barriers, and Implications for Policy

Preeti Zanwar, Ph.D., MPH, MS *has nothing to disclose.*

ODO4-16-06 Use-cases and users' requirements for design of an individualized sensor-based assistive system for people with dementia in nursing facilities - A user centered design approach using qualitative research

Stefanie Köhler, MA *has nothing to disclose.*

ODO4-17 Public Health: ADRD Risk And Protective Factors: Brain Changes And Mechanisms

ODO4-17-01 Lifetime cigarette smoking and later-life brain health: the population-based 1946 British Birth Cohort

Sarah-Naomi James, Ph.D. *has nothing to disclose.*

ODO4-17-02 The Effects of Mediterranean Diet on Memory and Alzheimer's Disease Biomarkers

Tommaso Ballarini *has nothing to disclose.*

ODO4-17-03 Neighborhood disadvantage is associated with accelerated cortical thinning and cognitive decline in cognitively unimpaired adults

Jack F.V. Hunt, BA *has nothing to disclose.*

ODO4-17-04 Association of Cerebrovascular Risk Burden with Mild Cognitive Impairment, Dementia and Brain Vascular Pathologies

Weili Xu, M.D., Ph.D. *has nothing to disclose.*

ODO4-17-05 Midlife cognitive activity moderates the relationship between brain tau deposition and late-life cognitive decline

Kang Ko, M.D. *has nothing to disclose.*

ODO4-17-06 Depressive symptom profiles predict dementia onset and longitudinal changes in hippocampal and white matter lesion volume in older persons. The AGES-Reykjavik Study

Lotte Gerritsen, Ph.D. *has nothing to disclose.*

ODO4-18 Public Health: Engaging People In ADRD Research

ODO4-18-01 World Alzheimer Report 2019 - Attitudes to dementia, global survey

Chris Lynch, BA (Hons) *has nothing to disclose.*

ODO4-18-02 Raising awareness of Alzheimer's clinical trials: Development of messages tailored to African American caregivers and individuals at-risk

Melissa McGowan, MHS *has nothing to disclose.*

ODO4-18-03 Boot Camp Translation of Alzheimer's Disease and the Engaging Communities of Hispanics for Aging Research (ECHAR) Network

Luis D. Medina, Ph.D. *has nothing to disclose.*

ODO4-18-04 The NC Registry for Brain Health: An Actionable Strategy to Include Under-Represented Groups in Alzheimer's Disease Research

Kathleen A. Welsh-Bohmer, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Verasci - Contracted Research

Takeda Pharmaceutical Co - Contracted Research

ODO4-18-05 Global networks to address inequities and disparities in dementia: the case of LAC-CD and GLoDePP

Mario A Parra, Ph.D., M.D. *has nothing to disclose.*

ODO4-18-06 Accountable Care Organizations and Racial and Ethnic Disparities among Patients with Alzheimer's and Related Dementia Diseases

Jie Chen, Ph.D. *has nothing to disclose.*

ODO4-19 Public Health: Innovative Methods In ADRD Research

ODO4-19-01 Characterizing clinical misdiagnosis of dementia using Medicare claims records linked to Rush Alzheimer's Disease Center (RADDC) cohort study data

Bryan D James, Ph.D. *has nothing to disclose.*

ODO4-19-02 Looking at competing events through a different lens in dementia research: Examples from the Rotterdam Study.

Liliana Paloma Rojas-Saunero, M.D. *has nothing to disclose.*

ODO4-19-03 Dementias Platform UK (DPUK): Facilitating Cross-Cohort Analysis in a Digital Age

Sarah D Bauermeister, Ph.D. *has nothing to disclose.*

ODO4-19-04 Phenome-wide associations with an Alzheimer's disease genetic risk score in UK Biobank: Identifying early indicators of disease

Scott C Zimmerman, MPH *has nothing to disclose.*

ODO4-19-05 The association between a parental family history of dementia and modifiable risk factors for dementia among middle-aged individuals: a Propensity Score-Matched study

Joyce Vrijisen, MSc *has nothing to disclose.*

ODO4-19-06 Association of Traumatic Brain Injury with Late Life Neuropathological Outcomes in a Community-Based Cohort

Laura E Gibbons, Ph.D. *has nothing to disclose.*

SFTS4-01 World-Wide FINGERS Network: the first global network of multidomain dementia prevention trials *on-demand presentations accompany this session and are recommended viewing in advance***

SFTS4-01-01 FINGER (Finland)

Miia Kivipelto *has nothing to disclose.*

SFTS4-01-02 Euro-FINGERS/UK FINGERS (Europe)

Alina Solomon, M.D., Ph.D. *has nothing to disclose.*

SFTS4-01-03 AgeWell.De (Germany)

Susanne Roehr, Ph.D. *has nothing to disclose.*

SFTS4-01-04 US-POINTER (USA)

Laura D. Baker, Ph.D. *has nothing to disclose.*

SFTS4-01-05 Can-THUMBS UP (Canada)

Haakon B. Nygaard, M.D., Ph.D. *has nothing to disclose.*

SFTS4-01-06 LATAM-FINGERS (Latin America)

Lucia Crivelli, Ph.D. *has nothing to disclose.*

SFTS4-01-07 AU ARROW (Australia)

Ralph N Martins, Ph.D. *has nothing to disclose.*

SFTS4-01-08 J-MINT (Japan)

Hidenori Arai, M.D., Ph.D. *has nothing to disclose.*

SFTS4-01-09 MIND CHINA (China)

Yongxiang Wang, Ph.D., M.D. *has nothing to disclose.*

SFTS4-01-10 SINGER (Singapore)

Christopher Chen, M.D. *has nothing to disclose.*

SFTS4-01-11 SUPERBRAIN (South Korea)

Seong Hye Choi, M.D., Ph.D. *has nothing to disclose.*

SO4-01 Dementia Care Research: Behavioral Interventions

SO4-01-01 Effectiveness of lifestyle and psychosocial interventions in reducing cognitive decline in older people: systematic review

Hassan Mansour, MSc *has nothing to disclose.*

SO4-01-02 A systematic overview of evidence for cognition-oriented treatments in older persons

Hanna Malmberg Gavelin, Ph.D. *has nothing to disclose.*

SO4-01-03 Cognitive training for people with dementia: A Cochrane Review

Alex Bahar-Fuchs, Ph.D. *has nothing to disclose.*

SO4-01-04 Preventing Loss of Independence through Exercise (PLIÉ) for Persons with Dementia: A Randomized, Controlled Trial

Deborah E Barnes, Ph.D., MPH *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Together Senior Health, Inc - Contracted Research

SO4-01-05 Music-with-Movement intervention for people with mild/early cognitive impairment: An effectiveness-implementation hybrid cluster randomized controlled trial

Daphne Sze Ki Cheung, Ph.D., MSc in Clinical Gerontology, BN *has nothing to disclose.*

SO4-01-06 Yoga Training Impacts Physical Function 12 Months Post Intervention for Care Partners of those with Mild Cognitive Impairment

Melanie Chandler, Ph.D. *has nothing to disclose.*

SO4-03 Developing Topic Session: Public Health and Epidemiology

SO4-03-01 The prevalence of mild cognitive impairment and dementia in the older prisoner population in England and Wales

Katrina Forsyth, MSc *has nothing to disclose.*

SO4-03-02 The Overlapping Effect of Population Demographics and Social Characteristics on COVID-19 and Alzheimer's Dementia in Chicago

Kumar B Rajan, Ph.D. *has nothing to disclose.*

SO4-03-03 Effects of Exercise Training on Cognitive Function of Older Adults with Cognitive Impairments: An Umbrella Review of Meta-Analyses

Patricia C Heyn, Ph.D., FGSA, FACRM *has nothing to disclose.*

SO4-03-04 Socioeconomic inequalities in dementia risk among a French population-based cohort: quantifying the role of cardiovascular health and vascular events

Noemie Letellier, Ph.D. *has nothing to disclose.*

SO4-03-05 Unpacking Recruitment and Retention Strategies of Latinx Healthy Adults-Older Adults in a Neuroimaging, Neuropsychology and Blood-Genetic Biomarkers Research Study

Mirella Diaz-Santos, Ph.D. *has nothing to disclose.*

CME CREDIT APPROVAL PENDING

SO4-03-06 Does antihypertensive use moderate the effect of blood pressure on cognitive decline in the elderly?

Matthew J Lennon, M.D. *has nothing to disclose.*

SO4-03-07 Association Between Amyloid PET and Health Outcomes: the IDEAS Study

Gil D. Rabinovici, M.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Life Molecular Imaging - Contracted Research

Eisai - Consulting Fees

GE Healthcare - Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agent

Avid Radiopharmaceuticals - Contracted Research

Eli Lilly - Contracted Research

SFRS4-01 Behavioral management: from prevention to intervention

SFRS4-01-01 Predictors of behavioral and psychological symptoms and caregiver burden in spousal caregivers of people with dementia: a longitudinal study

Brian Lawlor *has nothing to disclose.*

SFRS4-01-02 Continuous palliative sedation in nursing home residents with dementia suffering from extreme refractory BPSD symptoms: a qualitative study.

Raymond Koopmans *has nothing to disclose.*

SFRS4-01-03 The impact of green care farms and other innovative nursing home models on BPSD symptoms in every day life for people with dementia

Hilde Verbeek *has nothing to disclose.*

SFRS4-01-04 Defining agitation, apathy and other psychiatric symptoms in cognitive impairment and dementia: Why we need to intervene.

Mary Sano, Ph.D. *has nothing to disclose.*

SFRS4-02 Brain energy rescue interventions to treat or delay Alzheimer's disease

SFRS4-02-01 A phase 1b multiple ascending dose study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of a medium chain triglyceride supplement in Alzheimer's disease

Haakon B. Nygaard, M.D., Ph.D. *has nothing to disclose.*

CME CREDIT APPROVAL PENDING

SFRS4-02-02 Safety and target engagement profile of two oxaloacetate doses in Alzheimer's patients

Russell H Swerdlow, M.D. *has nothing to disclose.*

SFRS4-02-03 The Ketogenic Diet as a Potential Prevention or Therapeutic Strategy for AD

Suzanne Craft, Ph.D. *has nothing to disclose.*

SFRS4-02-04 Improved brain energetics and cognition after a 6-month ketogenic intervention in mild cognitively impairment: Final results of the Benefic Trial.

Stephen Cunnane, Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Nestlé Health Science - Contracted Research

Bulletproof - Contracted Research

Senotec - Ownership Interest

SSYM4-01 Ethics in Dementia

SSYM4-01-01 Ethical and Practical Challenges in Disclosure of APOE Genotype

J. Scott Roberts, Ph.D. *has nothing to disclose.*

SSYM4-01-02 Expectations And Effects Of Biomarker-Based Dementia Risk Prediction In MCI - The PreDaDQual Project

Ayda Rostamzadeh, M.D. *has nothing to disclose.*

SSYM4-01-03 Ethical Considerations On Individualized Risk Prediction In MCI – The ABIDE Project

Jetske van der Schaar *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Roche - Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agent

Prometheus -

Aegon -

SSYM4-01-04 Amyloid Disclosure in Mild Cognitive Impairment

Jennifer Lingler, Ph.D., CRNP *has nothing to disclose.*

SFTS4-02 The Lancet Standing Commission on Dementia Prevention, Intervention and Care 2020 - The launch

SFTS4-02-01 The Lancet standing commission on prevention, intervention and care. Potentially modifiable risk factors for dementia

Gill Livingston, MBChB, M.D. *has nothing to disclose.*

SFTS4-02-02 A lifecourse model of potentially modifiable risk factors for dementia

Naaheed Mukadam, BMBCh, MRCPsych, MA, MSc, Ph.D. *has nothing to disclose.*

SFTS4-02-03 Interventions for people with dementia and family carers

Geir Selbaek, Ph.D., M.D. *has nothing to disclose.*

SFTS4-02-04 Dementia and physical health including COVID-19 epidemic

Lon Schneider, M.D., MS *has nothing to disclose.*

SO4-02 Epidemiology: Dementia & Risk In Underrepresented Populations

SO4-02-01 Little Progress in Reducing Relative Racial Disparities in the Incidence and Prevalence of Dementia in the United States, 2000-2016

Melinda C Power, ScD *has nothing to disclose.*

SO4-02-02 Incident cognitive impairment in a longitudinal cohort of older adults in rural South Africa, 2014-19

Lindsay Kobayashi, Ph.D. *has nothing to disclose.*

SO4-02-03 Incident MCI and Dementia in Hispanic and non-Hispanic Whites: Implications for ethnic comparisons of risk in Alzheimer's Disease Center data

Hector Salazar, BSN *has nothing to disclose.*

SO4-02-04 Potential for primary prevention of dementia in low- and middle-income countries: a cross-sectional analysis of population attributable risk of dementia using twelve modifiable factors in population surveys of aging

Laurent Cleret de Langavant, M.D., Ph.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

SafelyYou - Ownership Interest

SO4-02-05 Survival differences in ethnic minorities with dementia: a systematic review and meta-analysis

Melissa Co *has nothing to disclose.*

SO4-02-06 APOE genotype, brain imaging, and neuropsychological testing markers of Alzheimer's Disease: data from the Strong Heart Study

Astrid M Suchy-Dicey, Ph.D. *has nothing to disclose.*

SSYM4-02 Dementia and Cognitive Health in LGBTQ Older Adults

SSYM4-02-01 Interventions For LGBTQ Older Adults With ADRD And Their Care Partners

Karen Fredriksen-Goldsen, Ph.D. *has nothing to disclose.*

SSYM4-02-02 The Epidemiology Of ADRD In LGBTQ Older Adults

Jason D. Flatt, Ph.D., MPH *has nothing to disclose.*

SSYM4-02-04 Sociolegal and Practice Implications of Caring for LGBTQ People with Dementia

Rosie Harding, LLB, LLM, Ph.D. *has nothing to disclose.*

SFTS4-03 Emergency Preparedness for Persons with Dementia: Governmental Action in a Time of Crisis

SFTS4-03-01 WHO's efforts on COVID-19 and dementia, older adults, long-term care

Tarun Dua, M.D., MPH *has nothing to disclose.*

SFTS4-03-02 Public Health Response to COVID-19 for Persons Living with Dementia in Communities, Acute Care, and Long-Term Care Settings

Lisa C McGuire, Ph.D. *has nothing to disclose.*

SFTS4-03-03 Supporting people with dementia during crises

DY Suharya, MPH *has nothing to disclose.*

SFTS4-03-04 Key considerations for dementia-capable emergency preparedness plans

David Hoffman, D.P.S., C.C.E. *has nothing to disclose.*

SFTS4-04 Evidence-Based Initiatives to Improve Quality Dementia Care in Long-Term and Community Based Settings: A U.S. Perspective

SFTS4-04-01 Overview of Association's Dementia Care Practice Recommendations and Provider Roundtable Initiatives

Douglas D. Pace, NHA *has nothing to disclose.*

SFTS4-04-02 Using Environmental Gerontology to Design Dementia Care Environments in the U.S.

Patrick Doyle *has nothing to disclose.*

SFTS4-04-03 Providing Opportunities for Meaningful Engagement and Individualized Care in Residential Communities - The Introduction of Engagement Therapy Treatment

Pauline L. Coram *has nothing to disclose.*

SFTS4-04-04 The Impact of a Trained Workforce Delivering Person Centered Home Care

Lakelyn Hogan *has nothing to disclose.*

SFTS4-04-05 Responding to a Resident's Behavioral Expression or Unmet Need: A practical, evidence-based, person-centered method of addressing, tracking, and trending behavioral expressions to enhance the resident's well-being

Rita Altman *has nothing to disclose.*

Alzheimer's Association International Conference® 2020

SFTS4-04-06 Enhancing the Engagement of the Senior Living Front-Line in Dementia Detection, Care, and Support Utilizing the Project ECHO Model

Letitia Jackson *has nothing to disclose.*

SFTS4-04-07 The Future of Falls Reduction - AI-Assisted Falls Reduction/Injury Prevention for Residents with Dementia

Juliet Holt Klinger, MA *has nothing to disclose.*

Friday, July 31, 2020, AAIC Disclosures

7-8 a.m. Central Daylight Time (North America)

11:30-11:50 a.m. CDT

[Alzheimer's Imaging Consortium] Year in Review (special duration: 20 minutes)

Year in Review

Rachel F. Buckley, Ph.D. *has nothing to disclose.*